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1.  ABSTRACT 
Amyotrophic lateral sclerosis is a so far untreatable fatal neurological disease where both up-
per and lower motor neurons (MNs) are selectively and progressively degenerated.  Alt-
hough its pathogenesis in the spinal MNs is shown to stem from abnormal down-regulation of 
mRNA of ADARB1 encoding RNA editing enzyme ADAR2, what factors cause this 
down-regulation is yet to be determined.  To infer an abnormality underlying the 
down-regulation of ADARB1 in the patients' MNs, the present study determined many tran-
scription factors (TFs) possibly activating alternative promoters of ADARB1 in the MNs, 
based on cap analysis of gene expression for laser-captured human MNs, multiple in silico 
analyses using public data and in vitro luciferase assay for the promoters of ADARB1.  The 
present results on the promoters suggested that ADARB1 in the MNs was differentially regu-
lated from spinal dorsal horn neurons and white matter by a set of multiple TFs forming an 
MN-specific complex.  Because age-dependent decrease of one MN-specific activator for 
the ADARB1 promoters has been previously reported in the non-ALS subjects, the present 
study implied that an age-dependent decrease of the ADARB1-regulatory TFs from an inher-
ently low expression level due to single nucleotide polymorphisms at their expression quanti-
tative trait loci induced the down-regulation of ADARB1 below a threshold level in the pa-
tients' MNs after middle life.  Further investigation into other TFs in the MNs will be neces-
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sary to reveal the whole picture of the abnormality driving the pathogenesis of sporadic amy-
otrophic lateral sclerosis. 
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2.  INTRODUCTION 
2-1.  Regulatory mechanism of transcription 
In general, transcription of a gene is regulated largely in three levels: cis-regulatory regions in 
the genome sequence, trans-acting factors and epigenetic effects. 
2-1-1.  Cis-regulatory regions in the genome sequence (1): a promoter 
A promoter drives transcription of messenger RNAs (mRNAs) and generally consists of two 
core promoters in 100 base pairs (bp) and transcription start sites (TSSs) residing at the center 
of each of these core promoters [Introduction Figures 1A and 1B]1–3.   It has been demon-
strated that the core promoter has several specific features in both DNA sequences and modes 
of transcription initiation.  The core promoter is thought to consist of specific DNA sequence 
motifs that are highly conserved among species (e.g., TATA-box and initiator)4–10, although 
no universal motif in the core promoter has been identified.  From a mode of transcription 
initiation, the core promoter is classified as either a focused or a broad core promoter4–6,11: a 
focused core promoter harbors a single or multiple TSSs within several nucleotides (nt), typi-
cally has a TATA-box, and is mostly observed in the spatially and temporally regulated 
genes; a broad core promoter has multiple weak TSSs within the length of approximately 50 ~ 
100 nt, lacks the characteristic core promoter motifs and is generally associated with house-
keeping genes.  Although these features are basically conserved in Drosophila and mam-
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mals4–6,11, mammalian broad core promoters specifically reside within a CpG island6, the re-
gion where over 200 CpG dinucleotides reside within a highly GC-enriched area12,13.  The 
TATA-box rarely resides within the mammalian broad core promoter associated with a CpG 
island7,14. 
 A paired TSSs within a promoter produces transcripts on both the plus and minus 
strands in bidirectional and simultaneous ways [Introduction Figure 1B], driven by discrete 
transcriptional machineries1–3,8,9,15,16.  Such transcripts are a pair of stable mRNAs16, or alter-
natively, a pair of a stable mRNA and an unstable, polyadenylated non-coding promoter up-
stream transcript (PROMPT17–19), defined by an axis of 5' splice sites and polyadenylation 
signals within 500 bp of the TSSs2,8,9,15,20,21.  This pair of TSSs lies within the same 
DNase-hypersensitive site (DHS) in a narrow window of 100 ~ 180 bp on average that is 
strictly and symmetrically flanked by nucleosomes1–3,9,15,20.  Hence, importantly, a promoter 
can be defined within a relatively narrow region. 
2-1-2.  Cis-regulatory regions in the genome sequence (2): an enhancer 
An enhancer is defined as a conserved DNA element8,9,22–24 that triggers transcriptional bursts 
at promoters within its topologically proximal region25–27 by producing bidirectional 
non-coding RNAs, named enhancer RNAs (eRNAs), within a single DHS8,9,15,22,23,28–30 [Intro-
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duction Figures 1C and 1D].  A single enhancer can activate some target promoters at the 
same time25,26,31, and conversely, multiple enhancers are connected with a single promoters in 
a tissue-specific manner22,32.  By clustering within an order of magnitude wider region, mul-
tiple canonical enhancers form a super enhancer33,34 (or stretch enhancer35), which reinforces 
expression of tissue- and cell-type-specific genes with highly concentrated eRNAs and tran-
scriptional machineries33,34,36, thereby determining the identity of the tissue and cell-type31,37.  
Tissue-specific canonical22,38–42, super34 and stretch enhancers35 are frequently linked to many 
disease-associated single nucleotide polymorphisms (SNPs), highlighting the importance of 
tissue-specific enhancers for pathogenesis. 
2-1-3.  Trans-acting factors: transcription factors 
Transcription is regulated in trans by both many proteins and long non-coding RNAs 
(lncRNAs43–46).  Because how lncRNAs regulate gene expression is largely still unknown, in 
this section I am going to describe only about protein regulators, transcription factors (TFs). 
 So far, more than one thousand TFs that cooperatively drive transcription by RNA 
polymerase II are known47–50.  By binding their specific DNA sequences called "consensus 
motifs" within cis-regulatory regions51–55, TFs act as either an activator or a suppressor for 
gene expression56: they are activators mainly when they bind to the center region between the 
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bidirectional TSSs within the cis-regulatory region28, whereas they tend to be suppressors 
when they bind closely adjacent to the TSSs9.  Expressed in a ubiquitous or tissue-specific 
manner47, TFs regulate expression of functionally-related genes57,58 in a tissue-specific manner 
in concert with other TFs and transcriptional co-factors39,48,59–61 through additive or synergistic 
effects54,62,63, based on their own tissue-specific hierarchical network59,64–66. 
 TFs are basically classified according to the similarities of their DNA binding do-
mains47,49, but they are also distinguished by two other criteria.  One criterion is the role for 
remodeling the chromatin50,62,67–69: pioneer TFs bind to their target DNA sequences within a 
nucleosome and recruit a chromatin remodeling complex there to remove the nucleosome at 
that position, thereby allowing other non-pioneer TFs to bind there.  Many TFs play this 
chromatin remodeling role in a situation-depending manner70,71.  The other criterion is the 
importance in the regulatory network of TFs33,65: master TFs (or core TFs) bind to super en-
hancers of the genes that are biologically important to that cell-type, thereby defining the 
identity of the cell.  Some master TFs also act as pioneer TFs (e.g., Oct4 and Sox233,65,69), 
implying a functional link between these two criteria. 
2-1-4.  Epigenetic effects: histone modifications and DNA methylation 
The third levels of transcriptional regulation are largely two epigenetic effects.  One of these 
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is a post-translational modification of histone proteins around the cis-regulatory regions de-
pending on the transcriptional activity: some modifications with methyl and/or acetyl groups 
on the N-terminal tail of a histone H3 protein render these cis-regulatory regions more acces-
sible to additional TFs and RNA polymerase II1,9,10,15,18,19,28,72,73 in a tissue- and 
cell-type-specific manner22,74,75.  Well-known modifications on the histone H3 for the active 
promoters and enhancers are tri-methylation at the lysine 4 (H3K4me3), and 
mono-methylation at the lysine 4 (H3K4me1) or acetylation at the lysine 27 (H3K27ac), re-
spectively; a ratio of H3K4me3 to H3K4me1 at the enhancers positively correlates with their 
activity76.  The other is methylation of a cytosine residue in CpG dinucleotides (mCpG), 
which modulates binding affinity of TFs to their targets harboring CpGs53 and inhibits the 
transcriptional initiation without affecting its elongation, thereby controlling the tis-
sue-specific usage of the alternative promoters12,77.  Highly expressed genes tend to have few 
mCpGs at their active promoter and abundant mCpGs within their gene body77–79. 
2-1-5.  Species-, tissue- and cell-type-specificity of gene expression 
The regulation of gene expression is highly specific to the species, the tissues and the 
cell-types57,64.  Namely, genes conserved among mammals are differently regulated by spe-
cies-specific ways at all the three levels described above47,48,80–82, resulting in the different pro-
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file of gene expression (i.e., transcriptome) among the mammalian species83,84.  Similarly, 
different tissues of the same species have different transcriptomes83,85–89 even in cell-type res-
olution (e.g., subtypes of neurons and glial cells in the brain90). 
2-2.  Amyotrophic lateral sclerosis and its etiology 
2-2-1.  Definition of amyotrophic lateral sclerosis 
Amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) is a neurodegenerative disease 
affecting motor function.  A pathological hallmark in a patient with this disease is progres-
sive and selective degeneration of both upper and lower motor neurons (MNs).  When so far 
healthy people in their middle age are affected with ALS, they can live in 3 ~ 5 years after the 
onset due to paralysis of muscles of respiration91.  Namely, ALS is a fatal disease.  Howev-
er, an etiology of this disease is currently not fully understood, leaving this disease incurable.  
Therefore, ALS is one of diseases whose etiology is to be elucidated and completely curable 
therapeutics is to be established. 
2-2-2.  Epidemiology of ALS and ALS-associated genes 
An incidence of ALS is about 2 per 100,000 population per year, in which there are sex dif-
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ferences (ratio of men to women is about 1.4:192) that weakens after menopause somehow93.  
World-wide prevalence of ALS is 1.0 ~ 11.3 per 100,000 depending on reports94,95. 
 No more than 10% of patients with ALS have a positive family history for the dis-
ease, and this subpopulation of the patients is designated as familial ALS92,94.  Genetic anal-
yses of patients with ALS all over the world have been linking nearly 50 genes to this dis-
ease92, including copper/zinc superoxide dismutase 1 (SOD1)96, fused in sarcoma (FUS)97,98, 
TAR DNA binding protein (TARDBP)99,100, optineurin101, valosin-containing protein102, ubi-
quilin 2103, profilin 1104, heterogenous nuclear ribonucleoprotein A1 (hnRNPA1)105, chromo-
some 9 open reading frame 72 (C9ORF72)106,107 and cyclin F (CCNF)108.  Regardless of such 
various mutations, more than 90% of the patients have a negative family history for ALS (i.e., 
sporadic ALS).  Although some mutations are also found in patients with sporadic ALS to a 
limited extent91 (e.g., SOD1109, FUS110, TARDBP99,100, hnRNPA1105, C9ORF72106,107,111,112, and 
CCNF108), associated genes and their proportions in all the ALS patients markedly differ be-
tween East Asian and Caucasian113, and none of these defined mutations has enabled to de-
velop effective therapeutics for ALS. 
2-2-3.  Hypotheses of sporadic ALS pathogenesis 
During the past several decades, many research groups have tried to elucidate pathogenesis of 
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ALS91 with, for example, axonal transport defects114, neurofilaments abnormalities115, de-
creased clearance of neurotransmitter glutamate116, oxidative stress117 and D-serine-induced 
glutamate toxicity118.  Among such hypotheses, adenosine deaminase acting on RNA 2 
(ADAR2)-glutamate receptor ionotropic, AMPA 2 (GluA2) hypothesis119 proposed and ex-
panded by the Kwak' s group is the most plausible.  This is because it well explains both the 
cause of death of MNs and pathological changes specifically found in patients’ MNs, based 
on an aberrant molecular cascade. 
2-2-4.  ADAR2-GluA2 hypothesis for the pathogenesis of sporadic ALS 
The ADAR2-GluA2 hypothesis proposes an abnormal molecular cascade underlying the 
pathogenesis of sporadic ALS, as illustrated in Introduction Figure 2A.  In MNs of patients 
with sporadic ALS, the expression of mRNA of ADAR2 is down-regulated in a dis-
ease-specific manner120, thereby allowing the expression of unedited RNAs with 
ADAR2-mediated adenosine-to-inosine positions, including the glutamine/arginine (Q/R) site 
in pre-mRNA of GluA2 protein, a member of subunits of al-
pha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors121.  When an 
unedited GluA2 subunit is included in an AMPA receptor, it renders this glutamate receptor 
permeable to Ca2+ ions122–124.  Through Ca2+-permeable AMPA receptors, exaggerated intra-
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cellular entrance of Ca2+ ions activates autophagy125 and calpain, a Ca2+-dependent cysteine 
protease.  This activated calpain then causes Transactivation Responsive Region-DNA 
binding protein of 43 kilodalton (TDP-43) to aggregate abnormally in the cytosol by cleaving 
TDP-43 into aggregation-prone fragments126 (known as TDP-43 pathology), and also disrupts 
nuclear pore complex (NPC) by cleaving its constituents nucleoporins127.  Indeed, both of 
TDP-43 pathology and the disruption of NPC specifically occur in the MNs of patients with 
ALS128–131.  Besides, when ADAR2 is conditionally knocked out with the Cre-loxP system in 
MNs of mice after birth, these mice named AR2 faithfully recapitulate the disease phenotypes 
of ALS described above132 [Introduction Figure 2B]: loss of ADAR2 in the MNs causes se-
quentially failure of RNA editing at the Q/R site of GluA2, activation of calpain, which re-
sults in generation of TDP-43 pathology, disruption of NPC, and activation of autophagy133. 
These sequential events ultimately result in death of the MNs and motor dysfunction in the 
AR2 mice.  Therefore, down-regulation of ADAR2 in the mouse MNs mimics both clinical 
features and pathological findings seen in the patients with sporadic ALS.  Moreover, 
down-regulation of ADAR2 mRNA is also reported in the MNs of an ALS patient carrying an 
FUSP525L mutation110 and decreased RNA editing levels at the Q/R site of GluA2 are observed 
in tissues of ALS patients with an abnormal expansion of G4C2 repeats in C9ORF72134, indi-
cating that the ADAR2-GluA2 hypothesis may partially explain the molecular cascade in he-
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reditary types of ALS, as well.  In short, down-regulation of ADAR2 mRNA and protein 
with resultant editing insufficiency at the Q/R site of GluA2 in the MNs may play a pivotal 
role in the pathogenesis of both sporadic and some types of familial ALS. 
2-3.  ADAR2 gene ADARB1 
When the first canonical coding exon of ADAR2 gene ADARB1 is designated as Exon 1135, 
ADAR2 protein has two nuclear localization signals and two double-stranded RNA binding 
domains residing in Exon 2, and an adenosine deaminase domain lying from Exon 4 to Exon 
6 [Introduction Figure 3]136,137.  So far ADARB1 is known to have 5 alternative exons: Exon 
1a135, Exon 0138, 5'-extended Exon 2139, Exon 5a140,141 and Exon 7a142.  In addition, ADARB1 
transcripts can be in four forms in the 3' region downstream of Exon 9: the longest form har-
boring retained Intron 9 (L-1), two longer ones (L-2 and L3) and the shortest (S)135,136.  Such 
multiple alternative exons can affect enzymatic activity of ADAR2 protein143. 
 By cap analysis of gene expression (CAGE)144, the Functional Annotation of the 
Mammalian Genome 5 (FANTOM5) Consortium has analyzed the transcriptional activity 
genome-widely at the a nucleotide level10,22,30, and determined that ADARB1 had five 
CAGE-defined TSSs (CTSSs): p1@ADARB1, p2@ADARB1, p3@ADARB1, 
 15 
p4@ADARB1 and p13@ADARB1 [see Introduction Figure 3], where the smaller number X 
in pX@Y defines a more intense and ubiquitous CTSS of Y gene10.  For simplicity, these five 
CTSSs of ADARB1 are abbreviated just to p1@, p2@, p3@, p4@ and p13@ hereafter.  Be-
cause of these five CTSSs, there are indeed various putative patterns of ADARB1 transcripts, 
many of which have high coding potential46 [Introduction Figure 4]; however, ADAR2 is 
enzymatically fully active only when it is translated from ADARB1 transcripts including Exon 
2 and being in one of the longer 3' end-forms (L-2 or L-3)136,140.  According to the previous 
reports10,22,30,135,138, the p1@ flanks the first 5' untranslated exon (Exon -2) and the p2@ lies in 
the region 714 bp upstream from the 5' end of the p1@; both CTSSs can produce full-length 
transcripts.  On the other hand, the p3@ and the p4@ reside at the exact 5' end of Exon 0 and 
the position 18 bp downstream from the p3@, respectively; the transcripts from them are de-
void of Exon -2, Exon -1 and Exon 1a.  The p13@ is located in the region within the gene 
body between Exon -2 and Exon -1, and its transcripts are depleted Exon -2.  Enzymatic 
competence of ADAR2 proteins expressed from the latter three CTSSs is currently undeter-
mined. 
 According to the FANTOM CAT v1.0.0 Extended View (v1, hg19) on the FANTOM 
Zenbu Browser (http://fantom.gsc.riken.jp/zenbu/)46 [see Introduction Figure 4], ADARB1 is 
expressed in insignificantly weak correlation with intergenic lncRNA LINC00162.  Besides, 
 16 
ADARB1 is apparently regulated by two super enhancers (~10 kilobases (kb) and ~110 kb in 
length) and other canonical primate-specific enhancers, because both of the two super en-
hancers harbor many expression quantitative trait loci (eQTL) of ADARB1 affecting its ex-
pression, and because many of its eQTL reside within DHSs whose DNA sequence is highly 
conserved among primates but poorly between humans and mice.  There are 18 CTSSs other 
than the five CTSSs of ADARB1 within the 231.8 kb region around ADARB1, suggesting po-
sitions of putative enhancers around this gene [annotated with "lnc" and "e" for lncRNAs and 
eRNAs, respectively, in Introduction Figure 4]. 
2-4.  Working hypothesis and problems that should be overcome in this study 
2-4-1.  Working hypothesis in this study 
When the ADAR2-GluA2 hypothesis holds true, why is mRNA of ADAR2 down-regulated in 
the MNs of patients with ALS?  Expression of ADAR2 and the edited form of its substrate 
have been demonstrated to decrease with aging in wild-type (WT) mouse spinal MNs145 and, 
corresponding phenomena are also observed in the brain of older humans compared to 
youngers146,147.  Based on these observations, I set a putative long-term pathogenic cascade of 
sporadic ALS as a working hypothesis in the present study: abnormally decreasing in an 
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age-dependent manner, some ADARB1-regulatory TFs would fail to maintain the normal ex-
pression of ADARB1 in the patient's MNs, thereby accelerating the age-dependent decrease of 
ADAR2 [Introduction Figure 5].  This working hypothesis fueled my interest in a regula-
tory mechanism of ADARB1 expression in the human MNs, because understanding this 
mechanism is vital to concretely predict an abnormality underlying the down-regulation of 
ADARB1 in the patients' MNs. 
2-4-2.  Problems that should be overcome in this study 
To investigate the regulatory mechanism of ADARB1 expression in the human MNs, this 
study should overcome the following big four problems: lack of specific profile of both ex-
pression of TFs and transcriptional activity of the ADARB1 alternative promoters in the hu-
man MNs; lack of established methods that enable to systematically infer all the 
ADARB1-regulatory TFs in the MNs; limited information regarding the regulators for expres-
sion of the human148,149 and murine150–152 ADAR2 genes; lack of ontological difference in the 
regulatory mechanism between human and mouse ADAR2 genes.  It is necessary to infer 
ADARB1-regulatory TFs in silico, because expression libraries of human TFs are not com-
pletely available and because it will be quite laborious to functionally screen all 
ADARB1-regulatory TFs whose library is available. 
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Introduction Figure 1  Definition of the promoter and enhancer, according to Andersson R. 
et al. Mol. Cell (2015)3 and Chen Y. et al. Nat. Genet. (2016)2. 
A, Structure of core promoters.  A TSS (+1) is indicated with an arrow, which resides at the 
center of a core promoter.  Both focus and broad core promoters are shown with positions of 
the TATA-box (thicker vertical line) and/or the initiator (thinner vertical line) and mRNA 
(red wavy line).  B, Structure of a promoter embraced by a CpG island (green).  The pro-
moter consists of a pair of bidirectional TSSs in 100 ~ 180 bp distance and is defined within a 
single DNase hypersensitive site (DHS) symmetrically flanked by nucleosomes with 
H3K4me3 modification (3 in an orange pentagon).  Red wavy line, mRNA; blue wavy line, 
non-coding promoter upstream transcript; H, histone.  C, Structure of an enhancer. The en-
hancer is also defined within the single DHS flanked by nucleosomes with H3K4me1 (1 in an 
orange pentagon) and H3K27ac (light blue triangle) modification.  In the enhancer, bidirec-
tional non-coding RNAs (enhancer RNAs) are transcribed.  D, Schema of the enhancer acti-
vating its target promoter.  Transcription levels are highly correlated between the enhancer 
and its target promoter. 
  
A 
B 
C 
D 
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Introduction Figure 2A  Scheme of ADAR2-GluA2 hypothesis of sporadic ALS patho-
genesis. 
Normal activity of ADAR2 in motor neurons of healthy people (left panel) is deteriorated in 
motor neurons of patients with ADAR2-mediated ALS, including sporadic, FUSP525L-caused 
and abnormal expansion of G4C2 repeats in C9ORF72-caused ALS (right panel).  As indi-
cated with a red question mark, what factor causes the down-regulation of ADAR2 expression 
is still unknown.  Although Ca2+ influx encircled by dotted line is confirmed only in sporadic 
ALS model mice AR2, this molecular event is sure to occur in the motor neurons of the pa-
tients as well [see Introduction Figure 2B].  AMPAR, AMPA receptor; Cyt, cytoplasm; 
ECM, extracellular matrix; NPC, nuclear pore complex; Nuc, nucleoplasm; TDP43, Transac-
tivation Responsive Region-DNA binding Protein of 43 kilodalton; FUS, Fused in Sarcoma.  
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Introduction Figure 2B  Molecular phenotype in the motor neurons of AR2 mice. 
ADAR2-conditionally knocked out mice AR2 (right panel) faithfully recapitulate the molec-
ular phenotype observed in the motor neurons of the patients.  Of note, such phenotype in 
AR2 mice can be rescued by intravenous injection of AAV9-ADAR2 expression vector153 or 
oral administration of anti-epileptic drug perampanel154, providing the rationale of potential 
therapeutics for sporadic ALS.  Abbreviations are the same as in Introduction Figure 2A. 
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Introduction Figure 4  Genetic environment around ADARB1. 
ADARB1 locus, CATs (CAGE-associated transcripts), its coding potential (1, 2, 3 and 4 are 
all putative enzymatically active coding sequences started from Exon 1a, Exon 0, Exon 1 ex-
cluding Exon 5a, and Exon 1 including Exon 5a, respectively), CTSSs (CAGE-defined TSSs) 
and total count of CAGE signals (e and lnc: CTSSs of enhancer RNA and other lncRNA, re-
spectively), CpG islands (green bar), eQTL (expression quantitative trait loci)-linked 
lncRNA-mRNA pair (green yellow), SNPs at eQTL of ADARB1 (black), super enhancers 
(brown), DHSs (DNase-hypersensitive sites; grey), and DNA sequence conservation among 
mammals (green signals; lack of signals indicates human-unique sequences).  All of these 
are publicly available data (see the Materials and methods Section). 
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Introduction Figure 5  Working hypothesis in this study. 
Abnormal age-dependent decrease of ADARB1-regulatory TF(s) in the motor neurons of pa-
tients with sporadic ALS (red line) compared to the healthy (black line) could cause the 
down-regulation of ADARB1.  When expression of the ADARB1-regulatory TF decreases 
below the threshold for maintaining the required expression of ADARB1 (blue horizontal line), 
at that time point (tTF) expression of ADARB1 might start being down-regulated.  A time 
point TADARB1 at which expression of ADARB1 becomes lower than the threshold to sufficiently 
mediate RNA editing at Q/R site of GluA2 (green horizontal line) may be the entrance for the 
pathogenesis of sporadic ALS already proposed by ADAR2-GluA2 hypothesis. 
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3.  MATERIALS AND METHODS 
3-1.  Strategy in this study 
To comprehensively seek human ADARB1-regulatory TFs in the MNs, this study adopted a 
strategy assuming species-, tissue- and cell-type-specific regulation of ADARB1 expression 
[Materials and methods Figure 1].  First, I genome-widely profiled transcriptional activity 
specific to laser-captured human MNs by conducting the CAGE on these neurons.  Next, 
based on this valuable CAGE data and supportive public data, I defined active promoters of 
ADARB1 in the MNs and all TFs expressed in the human MNs (motoneuronal TFs).  After 
this, I predicted ADARB1-regulatory TFs in the MNs by multiple approaches that mutually 
complimented and supported my prediction, with the best use of various public data of TFs.  
Fourth, I validated many ADARB1-regulatory TFs from the predicted TFs by in vitro lucifer-
ase assay for the ADARB1 promoters.  Then, based on the results of this assay and public 
data of protein-protein interactions and tissue-specific expression of the TFs, I deduced an 
MN-specific TF complex possibly regulating ADARB1 expression in the MNs.  Finally, I 
inferred a role of the ADARB1-regulatory TFs in the pathogenesis of sporadic ALS, based on 
public data of age- and polymorphism-dependent change in their expression, thereby propos-
ing an implication for the sporadic ALS pathogenesis. 
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Materials and methods Figure 1  Schema of the strategy in this study. 
Every procedure is shown with the number of the Results and Discussion Sections in brackets.  
CAGE, cap analysis of gene expression; MN, motor neuron; TF, transcription factor. 
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3-2.  Materials and methods in this study 
When a particular software or package was not denoted, all data management was performed 
by the free programming language R version 3.2.2155 on RStudio version 1.0.136156. 
3-2-1.  Data visualization of the genetic environment around ADARB1 
All information was visualized on the University of California, Santa Cruz Genome Browser 
(UCSC-GB; https://genome.ucsc.edu/) with GRCh38/hg38 human assembly.  The CTSSs 
around ADARB1 and CAGE total counts were retrieved via the track data hub of FANTOM5 
on the UCSC-GB.  All additional information of the genetic environment around ADARB1 
was extracted from the FANTOM CAT v1.0.0 Extended View v1 hg19 on the FANTOM 
Zenbu Browser (http://fantom.gsc.riken.jp/zenbu/)46, re-annotated from hg19 to hg38 using 
UCSC tool LiftOver (https://genome.ucsc.edu/cgi-bin/hgLiftOver), and then, visualized on 
the UCSC-GB; no insertion or deletion of nucleotides was observed during the re-annotation 
with LiftOver within the investigated region around ADARB1.  This information included 
the FANTOM5 data46 (CAGE-associated transcripts (CATs), coding potential determined by 
RNACode157, lncRNA-mRNA pairs linked with eQTL and positions of super enhancers), po-
sitions of DHSs38, SNPs at eQTL of ADARB1 affecting an expression level of this gene158, and 
positions of UCSC CpG islands. 
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3-2-2.  Extraction of total RNAs from spinal MNs, dorsal horns and white matter 
Frozen spinal cords of two autopsied non-ALS donors (donor 1 T-153 and donor 2 T-168) 
were respectively embedded in Tissue-Tek® O.C.T. Compound (Sakura Finetech) and sec-
tioned by a cryostat (Leica Microsystems) at -20 °C into 20 µm.  The sections were washed 
by methanol, dried in 5 minutes at the room temperature, stained by 0.1% toluidine blue, 
washed by 70% ethanol 5 times, washed by 100% ethanol, dried in 5 minutes at the room 
temperature, and then kept at -30 °C until following microdissection.  Storage buffer of la-
ser-captured MNs was prepared with RNeasy Micro Kit Buffer RLT (QIAGEN) and be-
ta-mercaptoethanol (ratio = 100:1 in volume).  From these sections, large anterior cells were 
recognized as MNs, and they were sampled one by one into the storage buffer with a laser 
capture microdissector (Leica Microsystems): 11,100 MNs were from donor 1 and 9,529 from 
donor 2 (in total, 20,629 MNs).  All the samples were kept at -80 °C until RNA extraction.  
For the controls, the dorsal horns and white matter of the donor 2 were also macroscopically 
sampled with a knife.  Total RNAs of all the samples were extracted using QIAGEN RNeasy 
Micro Kit (QIAGEN) according to the manufacturer’s instruction, respectively.  Sample 
collection and RNA extraction were conducted by Ms. Teramoto and me.  The experimental 
procedures were approved by the Ethics Committee of the University of Tokyo (Examination 
Number: G1396- (32)). 
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3-2-3.  Cap analysis of gene expression of human MNs, dorsal horns and white matter 
For the 6 sets of the extracted total RNA, CAGE144 was performed and the analyzed data files 
were provided by Genome Network Analysis Support Facility, RIKEN (Yokohama, Japan).  
The provided data files included bam files and bedGraph files mapped by BWA159 version 
0.7.10-r789 or TopHat2160 version 2.0.12 onto the hg19 annotation.  Before visualization of 
CAGE signals around ADARB1 on the UCSC-GB, all bedGraph files were re-annotated from 
hg19 to hg38 using the UCSC LiftOver. 
 Using these bam files, expression levels of CAGE tags in every sample were calcu-
lated in tag per million (tpm) by a series of commands in CAGEr R package161 as follows: 
normalizeTagCount(myCAGEset, method="simpleTpm"); clusterCTSS(myCAGEset, thresh-
old=1, nrPassThreshold=1, thresholdIsTpm=T, method="paraclu", maxDist=400, re-
moveSingletons=F); cumulativeCTSSdistribution(myCAGEset, clusters="tagClusters"); 
quantilePositions(myCAGEset, clusters="tagClusters", qLow=0.1, qUp=0.9); export-
ToBed(myCAGEset, what="tagClusters", qLow=0.1, qUp=0.9, oneFile=T); aggre-
gateTagClusters(myCAGEset, tpmThreshold=5, qLow=0.1, qUp=0.9, maxDis=400); getEx-
pressionProfiles(myCAGEset, what="consensusClusters", tpmThreshold=5, nrPassThresh-
old=1, method="som", xDim=4, yDim=2); exportToBed(myCAGEset, 
what="consensusClusters", colorByExpressionProfile=T); extractExpression-
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Class(myCAGEset, what="consensusClusters", which="all").  Pairwise correlations among 
the 6 samples were calculated using plotCorrelation(myCAGEset, samples="all", meth-
od="pearson") function in the CAGEr R package. 
 There was still no consensus on a definitive list for TFs function of which was con-
firmed in vivo or in vitro47.  Therefore, before I define motoneuronal TFs, two lists of TFs in 
previous studies10,50 were merged beforehand to make a whole list of human putative TFs, re-
sulting that 2,410 genes were defined as TFs in this study; this list consequently included not 
only bona fide DNA sequence-dependent TFs but also other genes broadly related to tran-
scription (e.g., genes encoding subunits of RNA polymerases).  Expression levels of TFs in 
the MNs were extracted by their names from data mapped by BWA and TopHat2 using 
BEDtools2162 after the bed files of the consensus cluster sorted by sortBed were annotated 
onto hg19 by bedtools intersect -s -wb -a -b in this package. 
3-2-4.  Processing of RNA-seq data from human tissues and cells 
In this study, two sets of RNA-seq data were analyzed: the Data Set 1 included 44 RNA-seq 
data from the human central nervous tissues83,163–166 [Materials and methods Table 1]; the 
Data Set 2 consisted of RNA-seq data from 60 various tissues, primary cells and MNs differ-
entiated from induced pluripotent stem cells (iMNs)39,83,88,89,163–168 [Materials and methods 
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Table 2].  After sra files were converted to fastq files using fastq-dump -I -gzip function in 
sratoolkit version 2.8.1-2 (https://www.ncbi.nlm.nih.gov/sra/docs/toolkitsoft/), the first quality 
control of all the files was performed with fastqc function in FastQC version 0.11.5 
(https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and adaptors in reads were 
trimmed by Trimmomatic169 version 0.36 with the following command for both a single-end 
and paired-end: java -jar trimmomatic-0.36.jar SE (or “PE” for the paired-end) -phred33 IL-
LUMINACLIP:[the name of the adaptor sequence file]:2:30:10 MAXINFO:40:0.7 
MINLEN:36.  After the quality control was conducted again in the same way as the first one, 
the filtered and trimmed reads were aligned by STAR170 version 2.5.2b to UCSC hg38 with 
annotation of GENCODE171 version 24 by STAR --genomeDir --readFilesIn 
--readFilesCommand gunzip -c --outFilenamePrefix --outSAMstrandField intronMotif 
--outSAMtype BAM SortedByCoordinate.  Then, the aligned reads were assembled by string-
tie -o -G -A -x chrM in StringTie-1.3.2d172 and then merged by stringtie --merge -G -o -i for 
both data sets, respectively.  With the merged transcriptome, the aligned reads were 
re-assembled by stringtie -o -e -B -G -A, and from the re-assembled transcriptome, tran-
script-level expression of the TFs was retrieved with their gene names, using Ballgown R 
package173 and referencing a protocol article174.  After the negligible transcripts less than 1 
fragments per kilobase mapped exon per million (FPKM)175 were discarded, gene-level ex-
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pression of the TFs was gained by summing up their transcript-level expression. 
3-2-5.  RNA-seq from spinal MNs of WT mice and its data analysis 
Single spinal MNs were collected from three WT C57BL/6 mice at 7 weeks old (Oriental 
Yeast Co., Ltd.) with the laser capture microdissector in the same way as described above.  
The numbers of the MNs collected by Ms Teramoto and me were 1,916 from WT-1, 1,933 
from WT-2 and 2,042 from WT-3.  After total RNA was extracted using QIAGEN RNeasy 
Micro Kit (QIAGEN), RNA quality was checked using Agilent RNA 6000 Pico Assay (Ag-
ilent Technologies), and then, sequencing libraries were prepared using SMARTer Stranded 
RNA-Seq Kit (Clontech) by Ms. Teramoto.  These libraries were sequenced using Illumina 
HiSeq2000TM by BGI Japan, and that institution provided data of the reads whose quality was 
controlled and adaptors were trimmed.  Succeeding data processing procedures were the 
same as those for the RNA-seq data from the human samples described above, except for an 
aligned genome UCSC mm10.  To visualize RNA-seq signals on the UCSC-GB, bedGraph 
files were produced from the aligned bam files sorted by the coordinate with index function in 
SAMtools176 version 1.3.1, by bamCoverage -b --normalizeUsingRPKM --outFileFormat 
bedgraph -o function in deepTools177 version 2.4.1. 
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3-2-6.  Investigation of conservation of TFs between human and mouse 
To search common TFs between human and mouse, only names and expression levels of the 
TFs were taken into consideration, and homology examination for neither DNA nor protein 
sequence was performed.  Because expression of 161 TFs was only detected in the public 
RNA-seq data from spinal MNs, their expression levels were input as 0 tpm.  On the other 
hand, the mean expression levels of the other 1,168 TFs (defined by BWA) and 1,046 TFs 
(defined by TopHat2) were calculated, respectively.  After expression levels of TFs that 
were uniquely detected by BWA or TopHat2 were set as 0 tpm in the other data, the final 
mean expression values were calculated between these two data based on BWA and TopHat2.  
Using this processed data, quartile of expression levels of the TFs in the human MNs were 
examined by quantile function in the R.  On the other hand, after the mean expression levels 
of the TFs among three WT mice were calculated, these mean values were used for examining 
the quartile.  The scatter plot was drawn using plot function in the default R. 
3-2-7.  Calculation of correlation coefficients among the CAGE signals 
The human CAGE summary data produced by the FANTOM5 Consortium10,22,30,178 with an-
notation (hg19.cage_peak_phase1and2combined_tpm_ann.osc.txt.gz) was downloaded from 
its website (http://fantom.gsc.riken.jp/5/datafiles/latest/extra/CAGE_peaks/).  Only human 
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tissue data in that file were used to investigate tissue-specific expression of the five CTSSs of 
ADARB1 [Materials and methods Table 3].  Pearson correlation coefficients and statistical 
significance among CAGE signals around ADARB1 detected by the FANTOM5 Consortium 
were calculated for central nervous tissue samples (n = 60) and for all of the samples of adults 
(n = 140), respectively, by pairs.panels function in psych R package179.  Statistical analyses 
were performed at the same time using this pairs.panels function, setting the significance 
threshold at 0.05. 
3-2-8.  Investigation of CAGE signals and histone modifications around ADARB1 in 
human tissues and HeLa-S3 cell line 
In addition to HeLa-S3 cells, I found only seven adult human tissues from which data of con-
comitant analyses of both CAGE and chromatin immunoprecipitation followed by 
high-throughput sequencing (ChIP-seq) for H3K27ac, H3K4me1 and H3K4me3 were availa-
ble: adipose, hippocampus, liver, pancreas, smooth muscle, spleen and substantia nigra.  All 
the CAGE data were extracted from the aforementioned annotated summary data downloaded 
from the FANTOM5 website.  The mean values of CAGE signals were calculated for repli-
cated samples: the biological replicates of adipose (n = 4), hippocampus (n = 3) and substantia 
nigra (n = 3), and the technical replicates of HeLa-S3 cells (n= 3).  For the other tissues, only 
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one data from a pooled sample was available.  ChIP-seq data of the tissues and the HeLa-S3 
cell line39 were downloaded via the website Gene Expression Omnibus 
(https://www.ncbi.nlm.nih.gov/geo/) with the accession numbers summarized in Materials 
and methods Table 4.  After re-annotation from hg19 to hg38 using the UCSC LiftOver, all 
the data were visualized on the UCSC-GB. 
3-2-9.  Quantification of mRNA of ADAR2 in adipose tissue and HeLa cells 
Total RNA was extracted from HeLa cells using the illustra RNAspin Mini RNA Isolation Kit 
(GE Healthcare Bioscience) according to the manufacturer's instruction.  Total RNA ex-
tracted from a human abdominal subcutaneous adipose tissue was purchased at Zenbio 
(RNA-T10-2; 10 μg of the RNA in 10 μL of 0.1 mM EDTA).  The provided donor infor-
mation was as follows: 49 year-old non-smoker female without medications; unknown ethnic-
ity; body mass index in average was 25.8; not diabetic nor reactive to viral DNA from HIV-1, 
HIV-2, HTLV I, HTLV II, hepatitis B and hepatitis C.  The provided Certificate of Analysis 
showed 7.8 in the RNA Integrity Number (RIN) of the RNA.  From this total RNA, cDNAs 
were reversely transcribed using ReverTraAce qPCR RT Kit (TOYOBO) and quantified by 
real-time quantitative PCR with a set of primers for mRNAs of ADAR2 or beta-actin on 
LightCycler System (Roche Diagnostics).  Primer sequences for ADAR2 from the 5' to the 3' 
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end were TTGGATCAGACGCCATCTC (19 nt; the forward) and 
GACAGCGTCAGCTAAAACCTG (21 nt; the reverse).  Primer sequences for beta-actin in 
the same direction were TCCTCCCTGGAGAAGAGCTA (20 nt; the forward) and CGTG-
GATGCCACAGGACT (18 nt; the reverse).  Before quantification, an internal standard 
specific to each of the genes was amplified using the same set of primers mentioned above.  
The set of standard DNA and cDNA were amplified in duplex in 20 μL of reaction mixture, 
composed of 10 μL of 2× LightCycler 480 Probes Master Roche (Roche Diagnostics) and 10 
μM of each primer and the Universal ProbeLibrary Probe (Roche Diagnostics; #48 and #27 
for ADAR2 and beta-actin, respectively) by PCR: pre-incubation at 95 °C for 10 min and am-
plification in 45 cycles of denaturation at 95 °C for 10 sec and annealing and extension at 
60 °C for 30 sec.  Finally, the expression level of mRNA of ADAR2 was normalized to that 
of beta-actin. 
3-2-10.  Calculation of correlation in expression between ADARB1 and TFs 
Correlation in expression with ADARB1 was calculated only for the 1,672 TFs defined by the 
FANTOM5 Consortium.  For calculation, 10 tissue samples in which ADARB1 was highly 
expressed and another 10 in which ADARB1 was lowly expressed were selected from the old 
Phase 1 data of the FANTOM5 Consortium downloaded via the Zenbu Browser (accessed on 
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Sep/2014), respectively [Materials and methods Table 5].  The expression levels of 
ADARB1 in those tissue samples was extracted from that data, whereas all expression levels 
of p1@TFs in the selected tissue samples were extracted from the old Phase 1 data of the 
FANTOM5 Consortium downloaded from its website at that time.  Spearman correlation 
coefficients in expression levels between p1@TFs and ADARB1 were calculated using cor 
function in the R.  No statistical analysis was performed during the calculation. 
3-2-11.  Search on a database for TFs probably targeting ADARB1 
ADARB1 was queried as a "target gene" on Open-access Repository of Transcriptional Inter-
actions (ORTI)180 (http://orti.sydney.edu.au/) only for "Homo sapiens" with the default other 
settings (accessed on Oct/2016).  The resultant table was analyzed manually. 
3-2-12.  Weighted gene co-expression network analysis 
As a preprocessing procedure for a weighted gene co-expression network analysis (WGC-
NA)90,181–183, a batch effect residing in the raw RNA-seq data in the Data Set 1 was observed in 
a principal component analysis by pca(method = "svd") function in pcaMethods R package184.  
Therefore, the batch effect in log2 (FPKM + 1)-transformed expression data of the whole 
genes was corrected as to the laboratories that had produced the raw data by ComBat function 
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in sva R package185.  Then, attenuation of the batch effect was confirmed by the principal 
component analysis, and from the batch-corrected data, expression data of all the TFs in the 
Data Set 1 were extracted.  Additionally, expression data of ADARB1 and non-TF marker 
genes for several types of neurons and non-neuronal cells90 were also extracted [Materials 
and methods Table 6]. 
 After this batch correction, the WGCNA was performed using WGCNA R package186 
on the following RNA-seq data in the Data Set 1 according to the developer's website 
(https://labs.genetics.ucla.edu/horvath/CoexpressionNetwork/Rpackages/WGCNA/): cerebel-
lum (n = 5)163, frontal cortex (n = 5)163, hippocampus (n = 4)164, motor cortex (n = 7)165, la-
ser-captured MNs from the non-ALS controls (n = 7)166 and temporal cortex (n = 3)83.  The 
RNA-seq data from laser-captured MNs of patients with sporadic ALS (n = 13) in the Data 
Set 1 were excluded from this WGCNA to investigate modules of TFs in the state of the hu-
man central nervous tissues free from ALS.  After confirmation of no outlier in all the data 
by hierarchical clustering, the following parameters were set: soft-thresholding power = 6, 
where mean connectiviey = 6.38, median connectivity = 3.88, max connectivity = 51.28; 
minimum cluster size = 25; deepSplit = 4.  Branches of the dendrogram were then cut by the 
Dynamic Tree Cut method by cutreeDynamic function, and the eigengene network was visu-
alized by plotEigengeneNetworks function.  Correlation between modules and expression 
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levels of ADARB1 and the marker genes was calculated by cor and corPvalueStudent func-
tions with the significance threshold at 0.05.  Bar plots and heat maps were drawn by plot 
function in the R and heatmap.2 function in gplots R package187, respectively.  To seek TFs 
significantly belonging to the Module Magenta, Bonferroni correction was adopted by multi-
plying the raw p-values by the number of the modules (n = 16) to counteract the problem of 
multiple comparisons. 
3-2-13.  Scanning ChIP-seq signals and consensus motifs of TFs 
Available ChIP-seq data of 571 TFs were manually downloaded one by one as bed files via 
ChIP-Atlas188 for all cell types with the significance threshold at 50 (accessed on Jun/2017).  
After the downloaded bed files were re-annotated from hg19 to hg38 using the UCSC LiftO-
ver, ChIP-seq signals within the promoter regions of ADARB1 defined in this study were 
scanned by the intersect -wb -a -b function in the BEDtools2. 
 Consensus motifs of 821 TFs from integrated data within rtfbsdb R package189, in-
cluding data of Catalog of Inferred Sequence Binding Preferences database51, and from manu-
ally collected data of JASPAR 2016190 and other articles52,53,55 were used to predict TF binding 
sites.  After the position frequency matrices in those data sources were converted into the 
position weighted matrices in probability ratio by toPWM function in TFBSTools R 
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package191, all the position weighted matrices were scanned around ADARB1 gene 
(chr21:45,010,086-45,230,085; hg38) by tfbs.scanTFsite function with threshold = 6 in the 
rtfbsdb R package.  Predicted TF binding sites within the defined promoter regions of 
ADARB1 were scanned from the output bed file by the intersect -wb -a -b function in the 
BEDtools2. 
3-2-14.  Search for TFs differentially expressed in ALS patients' tissues 
The following published supplementary data of previous studies were analyzed, in which the 
authors had investigated differentially expressed genes between sporadic ALS patients and 
non-ALS healthy controls in high-throughput ways: the RNA-seq-based data from la-
ser-captured MNs (13 cases, 9 controls)166,168; microarray-based data from laser-captured MNs 
and the remained anterior horns (12 cases, 10 controls), respectively192; RNA-seq-based data 
from the whole spinal cords (6 cases, 5 controls)193; and two sets of microarray-based data 
from motor cortices (31 cases, 10 controls194; and 11 cases, 9 controls195).  From these sup-
plementary tables and figure, all the TFs were extracted by their names or the provided probe 
IDs for the TFs.  Changes in ADARB1 expression were examined directly in these supple-
mentary data.  Their original criteria and methods for the statistical analysis were kept 
throughout this analysis.  For the microarray data from the laser-captured MNs and the re-
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mained anterior horns, the significance threshold was set at 0.05. 
3-2-15.  Seeking for TFs interacting with FUS protein 
TFs whose mRNAs were bound by FUS proteins were extracted by their names from the pub-
lished supplementary data of previous studies conducting crosslinking immunoprecipitation 
followed by RNA-seq (CLIP-seq) for FUS in human temporal cortex196, HeLa cells 197 and 
HEK293 cells198.  Similarly, TFs interacted by FUS proteins were extracted from the pub-
lished data of quantitative mass spectrometry following to immunoprecipitation of FUS in 
HeLa cells199.  The name of ADARB1 was searched directly in these supplementary data. 
3-2-16.  Prediction of TFs targeted by miR-141 and miR-200a 
To predict effects of miR-141 and miR-200a on expression of TFs, previous experimental da-
ta where these microRNAs had been overexpressed were downloaded via the Gene Expres-
sion Omnibus with the accession numbers GSM911074 (miR-141 transfection in A498 cells), 
GSM911072 (miR-200a transfection in A498 cells), GSM911081 (miR-141 transfection in 
Caki-1 cells) and GSM911078 (miR-200a transfection in Caki-1); while the former 2 data 
were thought to be unpublished, the latter 2 data were previously reported200.  From these 
processed data, fold-change values of all the TFs were extracted, and the mean value was 
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calculated for every TF detected by multiple probes.  Because ZEB1 and ZEB2 are estab-
lished targets of miR-141 and miR-200a201, a threshold for down-regulation was set to the 
same extent for their suppressed levels (0.75 fold-change), and its reciprocal number (1.33 
fold-change) was used as a threshold for up-regulation.  Fold-changes in expression of 
ADARB1 were also extracted and analyzed in the same way above.  Additionally, TFs that 
might be targeted by these two microRNAs was predicted in silico using TargetScan Human 
7.1202 (http://www.targetscan.org/vert_71/); after querying with the microRNA names on its 
website, all the TFs were screened by their names from the downloaded resultant tables. 
3-2-17.  Plasmid construction of the selected TFs 
All expression vectors of the selected 48 candidate TFs were constructed in the same way by 
Dr. Yamashita, Ms. Teramoto and Mr. Hosaka.  The coding sequence of the TFs was ampli-
fied using KOD -Plus- Ver. 2 (TOYOBO) from the template cDNA of HEK293 cells, HeLa 
cells, SH-SY5Y cells or human spinal cord.  The gel-purified PCR products were cloned into 
a pCI mammalian expression vector (Promega) using In-Fusion® HD Cloning Kit (Takara 
Bio).  The MAX Efficiency™ DH5α™ Competent Cells (ThermoFisher Scientific) trans-
formed by the plasmid were proliferated overnight under selection with carbenicillin in LB 
medium (Sigma-Aldrich) at 37 °C.  After the plasmid was purified using QIAprep® Spin 
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Miniprep Kit (QIAGEN), the insert sequence was verified by DNA sequencing [Materials 
and methods Table 7]. 
3-2-18.  Luciferase assay 
Among the four defined ADARB1 promoters, the p1, the p3/p4 and the p13 promoters were 
constructed in the same way.  First, the DNA sequence of every promoter was amplified 
from the human genomic DNA using KOD -Plus- Ver. 2 (TOYOBO) with the following pri-
mers shown from the 5' to the 3' end: TTTTTTGGTACCCAGCCGCGGTCTCTCAGC (30 
nt; forward) and TTTTTTAAGCTTGCACCCTCGCTTCTCCGC (30 nt; reverse) for ampli-
fication of the p1 promoter; TTTTTTGGTACCATTGATAGATTTTTTGTATTAGGATTTC 
(40 nt; forward) and TTTTTTAAGCTTCCGACGCCCCATGATGCTGAAAAAGGT (39 nt; 
reverse) for the p3/p4 promoter; TTTTTTGGTACCTAATGGCTTGCTGGTTGAAAACGC 
(36 nt; forward) and TTTTTTAAGCTTTCTCCATGAAAAGTCTTCTAAATACA (38 nt; 
reverse) for the p13 promoter.  Conditions of PCR were as follows: pre-incubation at 94 °C 
for 2 min and amplification in 25 cycles of denaturation at 98 °C for 10 sec and annealing and 
extension at 68 °C for 1 min (for the p1 promoter); pre-incubation at 94 °C for 2 min and am-
plification in 35 cycles of denaturation at 98 °C for 10 sec, annealing at 65 °C for 30 sec and 
extension at 68 °C for 30 sec (for the p3/p4 and the p13 promoters, respectively).  The 
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gel-purified PCR products were digested with restriction enzymes KpnI-HF and HindIII (New 
England Biolabs).  On the other hand, luciferase vector pGL4.15[luc2P/Hygro] (Promega) 
was also digested with the same restriction enzymes and dephosphorylated using Alkaline 
Phosphatase, Calf Intestinal (New England Biolabs).  Then, the digested amplicons and the 
luciferase vector were ligated using Quick Ligation Kit™ (New England Biolabs), respec-
tively.  The succeeding purification of the luciferase plasmids was conducted in the same 
way as the expression vectors were purified. 
 Construction of the other ADARB1 promoter defined in the present study, the p2 
promoter, was performed by Dr. Yamashita and Ms. Teramoto.  To circumvent a persistent 
mutation within the defined region, a wider region including the defined one was amplified 
from the human genomic DNA using KOD -Multi & Epi- (TOYOBO) with the following 
primers shown from the 5' to the 3' end: TGGCCTAACTGGCCGG-
GAGGCCAGGGCTAGTACAA (35 nt; forward) and TCTTGA-
TATCCTCGAAACAACTGCTCTTAAGACAA (35 nt; reverse).  PCR was performed in 
the following condition: pre-incubation at 94 °C for 2 min and amplification in 35 cycles of 
denaturation at 98 °C for 10 sec and annealing and extension at 68 °C for 1.5 min.  The 
gel-purified PCR products were digested with restriction enzymes DrdI and AlwNI (New 
England Biolabs), and the yielded fragment was blunted with Klenow Fragment (Takara Bio) 
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according to the manufacturer’s instruction, thereby gaining the insert sequence of the defined 
p2 promoter.  After the luciferase vector pGL4.15[luc2P/Hygro] were digested with 
KpnI-HF and XhoI, blunted with Klenow Fragment and then dephosphorylated with Alkaline 
Phosphatase, Calf Intestinal, the insert sequence and the prepared luciferase vector were li-
gated using Quick Ligation Kit™.  The MAX Efficiency™ DH5α™ Competent Cells trans-
formed by this plasmid were proliferated in the same way above, and from these cells plas-
mids were purified.  Because all the purified luciferase plasmids had the inverse sequence of 
the defined p2 promoter, these plasmids were digested with EcoRV and SfiI (New England 
Biolabs) and blunted with Klenow Fragment.  This digested product and the pCI vector that 
had been digested with EcoRI (New England Biolabs) and blunted with Klenow Fragment 
were then ligated in the same way.  The purified vector harboring the inverse sequence of 
the p2 promoter was digested with KpnI-HF and XhoI.  After this fragment and 
pGL4.15[luc2P/Hygro] digested with KpnI-HF and XhoI were ligated in the same way above, 
this product was transformed into the One ShotTM Stbl3TM Chemically Competent E. coli 
(ThermoFisher Scientific), and these cells were proliferated under selection with carbenicillin 
in LB medium at 30 °C for two days.  From these cells, the luciferase plasmids of the p2 
promoter were purified in the same way above. 
 All procedures of the following luciferase assay were performed by Ms. Teramoto.  
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After HeLa cells were seeded into 96-well plates, the cells were transfected with 0.1 μg of 
each plasmid of the ADARB1 promoters and 0.1 μg of each plasmid of the TF expression 
vectors using Lipofectamine® 3000 Transfection Reagent (Invitrogen).  The empty pCI ex-
pression vector was used as a negative control.  The cells in MEM-alpha medium (WAKO) 
with 10% fetal bovine serum (Invitrogen), 100 U/mL penicillin and 100 μg/mL streptomycin 
(Invitrogen) were cultured in 5% CO2 at 37 °C for 72 hours.  After this, the luciferase activ-
ity was measured with GloMax® Navigator (Promega) using the Luciferase Assay System 
(Promega) according to the manufacturer's instruction. 
3-2-19.  Visualization of CAGE data of the human primary memory T cells 
The CAGE signals of human primary CD4+ CD25high CD45RA- regulatory and CD4+ CD25- 
CD45RA- conventional memory T cells before and after in vitro expansion203 around 
ADARB1 were extracted from the aforementioned annotated summary data downloaded from 
the FANTOM5 Consortium website.  After bedGraph files in hg38 were produced using this 
data and the LiftOver, the CAGE signals around ADARB1 were visualized on the UCSC-GB. 
3-2-20.  Additional data analyses for the TFs examined by the luciferase assay 
Data of protein-protein interactions among the examined TFs was downloaded from 
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STRING204 version 10.5 and visualized using Cytoscape205 version 3.5.1; this data was based 
on the experiments, databases and co-expression (> 0.15 confidence).  Data of tis-
sue-specificity in expression of the TFs and their preference to be a hub were quoted from 
Supplementary Table S1 of Ravasi T. et al. Cell 201048.  Data of differentially expressed TFs 
with aging was extracted from Supplementary Table S12 of Mele M. et al. Science 201586.  
Data of SNPs at eQTL of the TFs in human tissues determined by the Genotype-Tissue Ex-
pression (GTEx) Consortium158 were downloaded via the FANTOM CAT v1.0.0 Extended 
View v1 hg19, and the effect of the alternative allele at these eQTL on  expression of the 
TFs was manually surveyed by browsing the GTEx Consortium website version V6p 
(https://www.gtexportal.org/home/).  Data of SNPs observed in patients with sporadic ALS 
were retrieved from ALS Variant Server206 (http://als.umassmed.edu/), ALS Data Browser207 
version 2 (http://alsdb.org/) and ALS Gene208 (http://alsgene.org/), respectively; only the ALS 
Variant Server provided data of the numbers of alleles counted in the patients.  All of these 
web resources mentioned here were accessed on Jul/2017. 
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4.  RESULTS 
4-1.  Genome-wide profile of transcriptional activity in human MNs by the CAGE 
method 
First of all, on assumption of species-, tissue- and cell-type-specific transcriptional activity 
and regulation of gene expression, in total 20,629 single human MNs were collected from au-
topsied spinal cords of two donors with laser capture microdissection209 (11,100 and 9,529 
MNs from each; i.e., two biological replicates) [Results Figure 1A]; the dorsal horns and 
white matter were macroscopically collected as controls, respectively.  RIN of the replicated 
samples of the MNs, the dorsal horns and the white matter were 4.2, 4.6, 7.7, 6.1, 6.2 and 5.9, 
respectively [Results Table 1A].  Then, I genome-widely profiled transcriptional activity in 
these samples by the CAGE method.  Since the starting amount of the total RNAs (0.45 ~ 
2.75 μg) was below the requirement (5 μg), each mapped read count of the samples was in an 
order fewer than the average in the FANTOM5 data178 [Results Table 1B].  Nevertheless, 
the resultant CAGE signals in the MNs were highly correlated between the biological repli-
cates and lowly correlated with those in the dorsal horns or white matter [Results Figure 1B], 
suggesting that the gained CAGE signals in the MNs faithfully represented genome-wide 
transcriptional activity specific to these neurons. 
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4-2.  Definition of promoters of ADARB1 
As a crucial step in the present study, I defined active promoters of ADARB1 in the human 
MNs based on the present CAGE data on the MNs and the previously annotated five CTSSs 
of ADARB1.  This enables to survey both species-specificity in the DNA sequences and po-
sitions of the promoters of the ADAR2 genes and tissue-specificity in activity of the ADARB1 
promoters in the adult human tissues. 
4-2-1.  Definition of the active promoters of ADARB1 in the human MNs 
Overview of the CAGE signals around ADARB1 in the MNs showed that the MNs consist-
ently expressed these signals around the p1@ and the p2@, but not in the exact position of the 
p13@, the p3@ or the p4@ [Results Figure 2A, bottom], suggesting that regions harboring 
the former two CTSSs were active promoters of ADARB1 in the MNs [Results Figures 
2B-D; Results Table 2]. 
 A single weak CAGE signal in the MNs was consistently detected at the p2@, which 
had no obvious PROMPT signal in the CAGE total counts [Results Figure 2B], probably due 
to technical limitation to detect unstable nascent RNAs in the CAGE method9.  A promoter 
of ADARB1 that was active in the MNs and harbored the p2@ was designated as p2 promoter 
and defined within a single DHS from approximately 300 bp upstream of the 5' end of the 
p2@ to 100 bp downstream of the 3' end of this CTSS (length: 412 bp); this definition was 
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according to a previous report210 and consistent with other previous reports that an active 
CTSS was flanked by the closest nucleosomes with the H3K4me3 modification at -250 ~ -350 
bp and about +100 bp72,211, respectively.  This p2 promoter has TATA-box (TATAAAAA) in 
a position unusually distant from the p2@ (more than -110 bp, compared to the canonical -33 
to -28 bp, relative to the CTSS6,11).  The DNA sequence of the p2 promoter was highly con-
served in a rhesus and partially in a marmoset, but not in a mouse. 
 The CAGE signals in the region around the p1@ suggested that this region was also 
an active promoter of ADARB1 in the MNs [see Results Figure 2B].  This active promoter 
in the MNs, designated hereafter as p1 promoter of ADARB1, was defined within a single 
DHS from 200 bp upstream of the 5' end of the p1@ to 320 bp downstream of the 3' end of 
this CTSS (length: 596 bp), which encompassed all the CAGE signals around the p1@ in the 
MNs and the previously defined two CTSSs p2@SSR4P1 and the p3@SSR4P110,22,30 of the 
putative ADARB1 PROMPT.  The DNA sequence of the p1 promoter was modestly con-
served with a marmoset and partially and weakly conserved with a mouse, whereas the se-
quence was in no homology with a rhesus.  This p1 promoter resided within a CpG island. 
 No CAGE signals were detected in the MNs at the p13@, which lacked an obvious 
PROMPT signal in the CAGE total counts [Results Figure 2C].  I defined a region from 
300 bp upstream of the 5' end of the p13@ to 100 bp of the 3' end of this CTSS as p13 pro-
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moter of ADARB1 (length: 435 bp) whose DNA sequence was highly conserved among the 
primates and to a lower extent with a mouse. 
 Similarly, in the MNs, no CAGE signals were detected at the p3@ nor the p4@, 
which had no obvious PROMPT signal in the CAGE total counts [Results Figure 2D].  I 
defined a region within a single DHS from 300 bp upstream of the 5' end of the p3@ to 100 
bp downstream of the 3' end of the p4@ as p3/p4 promoter of ADARB1 (length: 455 bp), 
whose DNA sequence was highly conserved throughout the primate species and modestly 
with a mouse. 
 In addition, the overview of the CAGE signals around ADARB1 in the MNs demon-
strated that many MN-specific CAGE signals were detected within and upstream regions of 
the gene body of ADARB1, implying the positions of putative MN-specific enhancers [see 
Results Figure 2A, bottom].  Accordingly, although none of these signals was at the exact 
positions of the previously detected CTSSs10,22,30, seven out of the 17 CAGE signals in the 
non-coding regions around ADARB1 in the MNs settled within the previously defined DHSs38. 
4-2-2.  Species-specificity of the promoters of the ADAR2 gene between humans and 
mice 
To survey difference in promoters of mouse ADAR2 gene Adarb1 from the human counter-
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parts, I investigated CTSSs of Adarb1 defined by the FANTOM5 Consortium10,22,30 [Results 
Figure 3A], revealing that among its three annotated CTSSs, only p1@Adarb1 and 
p2@Adarb1 had similar features to the human p1@ (e.g., their existence within a CpG island 
and presence of putative PROMPT Gm17769 in their 70 ~ 90 bp upstream), but the DNA se-
quence around these CTSSs was poorly conserved with humans [Results Figure 3B].  On 
the other hand, the position of the other p5@Adarb1 did not correspond to any of the human 
p2@, p3@, p4@ or p13@. 
 In conclusion, because the repertoire of the motoneuronal TFs and the promoters of 
the ADAR2 gene of humans were not conserved with mice, experiments on the regulatory 
mechanism of expression of mouse ADAR2 gene in the MNs could be of little help, and only 
analyses specific to the human MNs would elucidate the regulatory mechanism of ADARB1 
expression in the human MNs. 
4-2-3.  Tissue-specific activity of the ADARB1 alternative promoters 
To infer specificity in activity of the ADARB1 promoters among human adult tissues, I inves-
tigated transcriptional activity at the annotated five CTSSs of ADARB1 using the publicly 
available CAGE data from 140 different tissue samples of adults10,22,30,178.  Transcription at 
the p1@ within the p1 promoter was ubiquitously active among the tissues; at the p2@ within 
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the p2 promoter and at the p3@ and p4@ within the p3/p4 promoter, transcription was less 
ubiquitously active, respectively; and transcription at the p13@ within the p13 promoter was 
specifically detected in some of the nervous tissues [Results Figure 4A]. 
 To survey co-expression of the five CTSSs of ADARB1 in the human nervous tissues, 
I calculated correlation in expression of all the CTSSs within the 231.8 kb region around the 
ADARB1 using the CAGE data on the 60 nervous tissue samples within the aforementioned 
public CAGE data.  It demonstrated that the p1@, the p13@ and the p2@ were co-expressed 
in the 60 nervous tissue samples independently from the p3@ and the p4@ [Results Figure 
4B].  Consistently, as transcriptional activity of co-regulated promoters and that of their en-
hancers are highly correlated22,28, this result also showed that the p1@, the p2@ and the p13@ 
may be regulated by a different set of enhancers from the p3@ and the p4@ in the nervous 
tissues.  This independency of the p3@ and the p3@ was also observed even in calculation 
using the CAGE data on all the 140 tissue samples.  Indeed, previous CAGE data from hu-
man primary CD4+ CD25high CD45RA- regulatory and CD4+ CD25- CD45RA- conventional 
memory T cells203 showed the otherwise quiescent p3@ and p4@ were independently acti-
vated during the in vitro expansion212 [Results Figure 4C], suggesting independent and dy-
namic regulation of the p3/p4 promoter depending on a biological state of the cells. 
 To survey tissue-specific activity of the ADARB1 promoters from a viewpoint of the 
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histone modifications, I additionally analyzed the publicly available CAGE10,22,30,178 and 
ChIP-seq39 data for the active enhancer markers (H3K27ac and H3K4me1) and the active 
promoter marker (H3K4me3) in human seven tissues (adipose, hippocampus, liver, pancreas, 
smooth muscle, spleen and substantia nigra) and the HeLa-S3 cell line [Results Figure 5].  
Among these, the p1@ was the most active CTSS in all the samples but the adipose tissue 
where the p2@ was more active than the p1@; the p3@ and the p4@ were weakly or scarcely 
expressed and the p13@ was inactive in all of these data.  In accord with the lower CAGE 
signal at the p1@ in the adipose than that in the HeLa-S3 cell line, the commercially available 
total RNA from an adipose tissue indeed expressed fewer mRNAs of ADAR2 than HeLa cells 
(4.9×10-3 in adipose and 1.2×10-2 in HeLa cells, respectively, when the expression level of 
ADAR2 was quantified and then normalized to that of beta-actin by quantitative PCR).  As 
shown in Results Figure 5A, ChIP-seq peaks of the H3K27ac and H3K4me1 appeared at 
different positions in different tissues and cell line, implying tissue- and cell-type-specific 
combinatorial usage of enhancers22 for regulating ADARB1 expression.  In addition, a closer 
view around the p1@ and the p2@ revealed multiple peaks of the H3K4me3 around these 
CTSSs [Results Figure 5B]; the patterns of the multiple peaks were quite different between 
the adipose tissues actively expressing the p2@ and the other tissues dominantly expressing 
the p1@, demonstrating the difference in this histone modification reflecting the different ac-
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tivity of these two CTSSs. 
 In conclusion, the results of these investigations altogether suggested the tis-
sue-specific regulation of the ADARB1 promoters by enhancers specific to that tissue. 
4-3.  Definition of the human motoneuronal TFs 
To define the human motoneuronal TFs, I analyzed the present CAGE data on the human 
MNs and publicly available RNA-seq data on the laser-captured MNs of seven non-ALS 
adults166 for complementing the relatively limited CAGE signals in the MNs.  The CAGE 
data defined 1,173 motoneuronal TFs [Results Figure 6]; by adding 161 TFs uniquely de-
tected in the public RNA-seq data, I defined in total 1,334 human motoneuronal TFs. 
 Next, to survey difference in the motoneuronal TFs between humans and mice, I an-
alyzed RNA-seq data on approximately 2,000 laser-captured MNs of WT mice (n=3) [Results 
Table 3], defining 1,225 mouse motoneuronal TFs.  Humans shared 74% of their motoneu-
ronal TFs (988 out of 1,334) with mice; these shared motoneuronal TFs were in modest cor-
relation in expression (Pearson's rho = 0.58, p < 2.2e-16) [Results Figures 7A, left and 7B].  
However, humans shared with mice only 33% (223 out of 668) of their TFs expressed greater 
than the median expression level of the human motoneuronal TFs [Results Figure 7A, right], 
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demonstrating species-specificity in the expression and repertoire of the motoneuronal TFs. 
4-4.  Prediction of motoneuronal TFs regulating ADARB1 expression 
A large number of the human motoneuronal TFs required to select a subset of them that were 
preferentially examined by in vitro luciferase assay.  Thus, I predicted ADARB1-regulatory 
TFs in the MNs by multiple in silico analyses, based on (1) correlation in expression between 
each of the TFs and ADARB1, (2) a database for putative target genes of TFs, (3) correlation 
in expression between TF modules and ADARB1, (4) public data of ChIP-seq and consensus 
motifs of TFs, (5) TFs decreased in tissues of patients with sporadic ALS, and (6) possible 
molecular cascades of pathogenesis of mutant FUS-linked ALS. 
4-4-1.  Prediction from correlation in expression between each of the TFs and ADARB1 
TFs correlatively expressed with ADARB1 might regulate ADARB1 expression.  Therefore, I 
calculated the correlation between each of the TFs and ADARB1 using the previous CAGE 
data from highest and lowest 10 human tissue samples expressing ADARB110,22; this resulted 
in 32 TFs above the threshold (|Spearman's rho| ≥ 0.7), 24 of which were motoneuronal ones 
[Results Table 4]. 
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4-4-2.  Prediction from a database for putative target genes of TFs 
Database ORTI180 informs putative TFs targeting a particular gene based on previous 
low/high-throughput experiments and computational prediction.  For ADARB1, this database 
showed six putative TFs as its regulator (AR, E2F4, ETS1, FOXP3, GATA2 and TP53), 
among which AR and E2F4 were the motoneuronal TFs. 
4-4-3.  Prediction from correlation in expression between TF modules and ADARB1 
To find a subset of TFs ("module") regulating ADARB1 in neurons in the central nervous tis-
sues, I conducted WGCNA that enabled to dissect genes expressed in heterogeneous tissues 
into multiple modules that may have tissue- or cell-type-specific function85,90,181–183.  Unfor-
tunately, the number of available RNA-seq data from the laser-captured MNs (n= 7) of 
non-ALS adults166 was below the requirement to perform this WGCNA meaningfully (n > 15).  
Therefore, I conducted WGCNA using expression profiles of all TFs detected at least one 
sample by RNA-seq on cerebellum (n = 5)163, frontal cortex (n = 5)163, hippocampus (n = 4)164, 
motor cortex (n = 7)165, the laser-captured MNs (n = 7)166 and temporal cortex (n = 3)83 in the 
Data Set 1 (in total 1,986 TFs).  The WGCNA divided these TFs into 15 modules (colored) 
and one unclassified group (Module Grey) [Results Figure 8A]; 10 of these 15 colored mod-
ules formed the largest cluster based on their first principal component213 ("module 
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eigengene") [Results Figure 8B], indicating inter-modular functional relationship within this 
module cluster.  On the other hand, module eigengene of Module Magenta clearly distin-
guished the MNs from the other central nervous tissues [Results Figure 8C]; four TFs nega-
tively contributing to this eigengene were expressed only in the MNs, one of which was a 
well-known MN-marker gene MNX1 encoding Hb9 protein [Results Figure 8D]. 
 Next, to find putative neuron-specific modules regulating ADARB1 expression, I 
examined correlation of all the module eigengenes with expression of ADARB1, an 
MN-marker gene CHAT and each of 10 other marker genes for eight cell-types (neurons, glu-
tamatergic neurons, interneurons, Purkinje cells, astrocytes, oligodendrocytes, microglial cells 
and meningeal cells90) in these central nervous data, respectively [Results Figure 8E].  Even 
though I failed to find correlation between the expression of CHAT and any module 
eigengenes due to its low expression levels, the eigengenes of the six Modules correlating 
various neuronal marker genes (Turquoise, Blue, Brown, Red, Green and Black) were 
strongly and positively correlated with the expression of ADARB1.  All of these six modules 
within the largest module cluster embraced 91.6% of the TFs (339/370) whose expression was 
significantly correlated with the ADARB1 expression in this WGCNA.  Because 235 out of 
339 were the motoneuronal TFs, they were regarded as putative ADARB1-regulatory TFs in 
the MNs. 
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4-4-4.  Prediction from public data of ChIP-seq and consensus motifs of TFs 
Possibility of TF for binding to the ADARB1 alternative promoters could be predicted from 
the presence of their ChIP-seq signals and their consensus motifs within the defined regions.  
Among the 340 motoneuronal TFs whose ChIP-seq data were available in ChIP-Atlas188, no 
more than 60 TFs similarly bound to the p1, p2 and p3/p4 promoter, respectively [Results 
Table 5], suggesting that the p3/p4 promoter is likely regulated as actively as the p1 and the 
p2 promoters are done in the cells.  However, only MAX bound to the p13 promoter in the 
available data.  On the other hand, among the 328 motoneuronal TFs whose consensus mo-
tifs were available in public52,53,55,189,190, the motifs of less than 150 TFs were detected within 
each of the ADARB1 promoters [see Results Table 5], in many cases of which these positions 
were overlapped by the corresponding ChIP-seq signals, validating this in silico motif search. 
4-4-5.  Extraction of TFs decreasing in the tissues of patients with sporadic ALS 
Because TFs decreasing in tissues of patients with sporadic ALS might be involved in the 
down-regulation of ADARB1 in those tissues, I extracted such down-regulated TFs from the 
published high-throughput data on tissues of the patients and the non-ALS controls: 1) 
RNA-seq data from laser-captured MNs (13 cases, 9 controls)166,168; 2) microarray data from 
laser-captured MNs and the remained anterior horns (12 cases, 10 controls)192; 3) RNA-seq 
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data from the whole spinal cords (6 cases, 5 controls)193; 4) microarray data from motor corti-
ces (31 cases, 10 controls)194; and 5) another microarray data from motor cortices (11 cases, 9 
controls)195.  Conducting unsupervised hierarchical clustering based on gene expression, 
Aronica E. et al. reported that all the samples were divided into 3 groups: SALS1 group (18 
cases and 1 control), SALS2 group (13 cases and 2 controls) and Control group (7 controls)194.  
As a result of this analysis, in total 619 motoneuronal TFs were regarded as candidates for the 
ADARB1-regulatory TFs [Results Table 6]. 
4-4-6.  Extraction of TFs in possible molecular cascades of pathogenesis of mutant 
FUS-linked ALS 
RNA-binding protein FUS196,198,214 regulates gene expression via alternative splicing168,215,216 
and polyadenylation217 (extensively reviewed elsewhere218); and ALS-linked mutant FUS de-
teriorates such biological functions197,199,219, and also forms abnormal aggregation in the cyto-
plasm97,98.  Another report suggested the role of long-term effects from aberrant 
FUS-miR-141/200a feed-back loop in the pathogenesis of mutant FUS-linked ALS220.  It has 
been unclear, however, whether mutant FUS causes ALS phenotype through disruption of 
these known biological functions.  A recent report demonstrated that expression of ADARB1 
is decreased in MNs of an ALS patient carrying an FUSP525L mutation110 raised the possibility 
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that mutant FUS may have a role in ADARB1 regulation.  To assess the role of mutant FUS 
in down-regulation of ADARB1, I investigated the possibility that mutant FUS may facilitate 
sequestration of either mRNAs (Putative link I) or proteins (Putative link II) of the regulatory 
TFs and/or ADARB1 into cytoplasmic aggregation or (Putative link III) suppress the regula-
tory TFs and/or ADARB1 through miR-141 and/or miR-200a up-regulation. 
 For the Putative link I, mRNAs of 834 and 579 motoneuronal TFs in total bound to 
WT and mutant FUS (FUSR521G or FUSR521H), respectively, in previous data of CLIP-seq for 
FUS in human temporal cortex196, HeLa cells197 or HEK293 cells198 [Results Table 7].  The-
se public data also showed that mRNAs of ADARB1 bound to WT FUS in HeLa and HEK293 
cells but not to mutant FUS in HEK293 cells.  Another previous data199 showed protein-level 
interaction of 48 motoneuronal TFs with FUS in HeLa cells (the Putative link II); ADAR2 
does not interact with FUS in this cell line.  According to microarray data of renal cell car-
cinoma cell lines with miR-141 and miR-200a overexpression200, 99 ~ 191 motoneuronal TFs 
were suppressed by each of these microRNAs to the similar levels of their well-known targets 
ZEB1 and ZEB2, respectively (the Putative link III); TargetScan Human 7.1202 predicted 220 
~ 255 TFs as putative targets of these two microRNAs.  On the other hand, expression of 
ADARB1 was not affected by miR-141 but up-regulated by miR-200a in both of the cell lines 
(1.4 ~ 1.5 fold-change). 
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4-5.  In vitro luciferase assay of the selected TFs 
After these in silico predicting analyses, in total hundreds of motoneuronal TFs were listed up 
as candidates for ADARB1-regulatory TFs.  Among these candidates, in total 34 motoneu-
ronal and 14 non-motoneuronal TFs were selected to preferentially examine their regulating 
properties for the four ADARB1 promoters by in vitro luciferase assay [Results Figure 9; 
Results Tables 8A and 8B].  These candidate TFs included two motoneuronal and eight 
non-motoneuronal TFs that had been randomly selected before the present study, based on 
homology in DNA sequences around the first exon of ADARB1 among a human, chimpanzee, 
mouse and rat. 
 Luciferase assay was conducted not only for the p2 and p1 promoters active in the 
MNs but also for the p13 and p3/p4 promoters to ask if these quiescent promoters in the MNs 
could be regulated by the same TFs as the active ones were done.  Co-transfecting each of 
the selected TFs with each of the four promoters in the HeLa cells, respectively, revealed that 
all the four regions defined in the present study were competent as a promoter and each of 
them was regulated by a different set of the examined TFs [Results Figure 10A].  Among 
the examined 34 motoneuronal TFs, 15, 13, 21 and 23 TFs activated and 4, 8, 3 and 3 TFs 
suppressed transcriptional activity at the p2, the p1, the p13 and the p3/p4 promoters, respec-
tively; 3 and 2 TFs activated and suppressed only one of the promoters, respectively; 21 and 5 
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TFs activated and suppressed multiple promoters, respectively (cutoff: 3/2 and 2/3 
fold-change to the negative control for up- and down-regulation, respectively).  Seven out of 
the 21 activators for multiple promoters activated all the four promoters (i.e., universal acti-
vators: ESRRG, ID4, KLF7, NFIA, NR3C1, NR3C2 and ZEB1); one out of five suppressors 
for multiple promoters suppressed all the promoters (i.e., a universal suppressor: YBX1).  
Only one motoneuronal TF, MXI1, exhibited no effect on any of the tested ADARB1 promot-
ers.  On the other hand, among the 14 examined non-motoneuronal TFs, 5, 4, 7 and 7 TFs 
activated and 1, 6, 1 and 2 TFs suppressed the p2, the p1, the p13 and the p3/p4 promoters, 
respectively, and FOXD1 and FOXP3 activated all the four promoters [Results Figure 10B]. 
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Results Figure 1A  Laser capture microdissection of human spinal motor neurons (MNs). 
Larger anterior horn cells are regarded as MNs and selectively collected with the microdis-
sector.  Representative pictures before and after dissection are shown in left and right panels, 
respectively.  The margin of the anterior horn is depicted with white dotted line.  Inset in 
each panel shows a 2-fold-magnified view in a region indicated by the white rectangle.  The 
scale (200 µm) is shown at the bottom left. 
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Results Figure 1B  Correlation among CAGE signals detected in the laser-captured motor 
neurons, dorsal horns and white matter (aligned by BWA). 
CAGE signals in the two biological replicates of the MNs are highly correlated with each 
other but just weakly with those in technical replicates of dorsal horns and white matter, 
demonstrating specificity of the CAGE signals in the MNs. 
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Results Figure 4A  Tissue-specific expression of the 5 CTSSs of ADARB1. 
Expression levels of every CTSSs in all the human tissue samples are shown in TPM (tag per 
million).  All the human samples of healthy adults are categorized with different colors as to 
tissue-types.  The number of samples in each category is indicated in brackets.  All of the 
raw data are retrieved from the FANTOM5 web site; for names of these tissue samples, see 
Materials and methods Table 3. 
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Results Figure 4C  Example of independent and dynamic regulation of the p3@ and the 
p4@ in memory T cells. 
Transcriptional activity of ADARB1 at the p1@ and the p2@ (top), at the p3@ and the p4@ 
(bottom left) and at the p13@ (bottom right) before and after in vitro expansion of two kinds 
of memory T cells is shown, respectively.  CAGE signals on the plus and minus strands be-
fore and after the expansion are shown in different colors, respectively, as indicated in each 
row.  The raw data are downloaded from the FANTOM5 web site (see the Materials and 
methods Section).  The scale (200 bp) is shown in the top right of each panel. 
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Results Figure 5A  Transcriptional activity and histone modifications around ADARB1 in 7 
human tissues and HeLa cells. 
CAGE signals (red, the plus strand; blue, the minus strand) and ChIP-seq signals for histone 
H3K27ac (light blue), H3K4me1 (dark blue) and H3K4me3 (orange) in human adipose (n = 
4), hippocampus (n = 3), liver (n = 1), pancreas (n = 1), smooth muscle (n = 1), spleen (n = 1), 
substantia nigra (n = 3) and HeLa cells (n = 3) are visualized, respectively.  For CAGE sig-
nals in adipose, hippocampus, substantia nigra and HeLa cells, the mean values of their repli-
cates are shown, respectively.  Note that the scale of CAGE signals in smooth muscle differs 
from the others, and that because of their auto scales, ChIP-seq signals are not comparable 
with each other.  All of these are publicly available data (see the Materials and methods Sec-
tion).  The scale (100 kb) is indicated at the top. 
  
 86 
Results Figure 5B  Transcriptional activity and histone modifications around ADARB1 in 7 
human tissues and HeLa cells (view around the p1@ and the p2@). 
All scales, annotations and colors are the same as those in Results Figure 5A.  All of these 
are publicly available data (see the Materials and methods Section).  The scale (2 kb) is in-
dicated at the top. 
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Results Figure 6  The numbers of TFs detected in the motor neurons (MNs) by the present 
CAGE and the previous RNA-seq. 
The number of TFs found in the present data of CAGE from the MNs aligned by BWA (blue) 
or TopHat2 (light blue) and in the publicly available previous RNA-seq data is indicated in 
brackets, respectively.  In total, 1,334 TFs are defined as motoneuronal TFs without duplica-
tion. 
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Results Figure 7A  The number of motoneuronal TFs expressed both in humans and mice. 
As a whole, 988 motoneuronal TFs are overlapped between humans and mice (left).  Ap-
proximately only one-third of the motoneuronal TFs are commonly expressed between the 
two species at a level greater than the median expression level of total motoneuronal TFs 
(right).  The total number of human and mouse TFs is shown in brackets, respectively. 
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Results Figure 7B  Correlation in expression between human and mouse motoneuronal TFs. 
Expression levels of 988 motoneuronal TFs are just modestly correlated between human (light 
blue) and mouse (dark blue).  A red line shows a result of linear regression, and Pearson's 
rho is indicated also in red.  Lines in light and dark blue display the median of the expression 
levels of the human and mouse TFs, respectively.  Dotted lines in light and dark blue are the 
lower or upper quartile of the expression levels of the human and mouse TFs, respectively. 
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 Results Figure 8A  Dynamic tree cut in the WGCNA. 
WGCNA (Weighted gene co-expression network analysis) with the dynamic tree cut divides 
TFs expressed in the human central nervous tissues into the 15 colored modules and one un-
classified group (Module Grey). 
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Results Figure 8B  Adjacency of the eigengenes of the 15 modules. 
The module eigengene (first principal component) shows the large cluster consisting of 10 
modules (upper left).  Module colors are depicted at the left and bottom.  The modules 
within the large cluster may be functionally related with each other.  The color key at the 
right side indicates the adjacency (1 + cor(Ei, Ej))/2, where Ei and Ej are the module 
eigengene of Module i and j, respectively, and cor(Ei, Ej) is Pearson' rho between Ei and Ej. 
  
 92 
Results Figure 8C  Module eigengene of all the modules. 
All module eigengenes in cerebellum (n = 5), frontal cortex (Frontal Cx; n = 5), hippocampus 
(Hippo; n = 4), motor cortex (Motor Cx; n = 7), temporal cortex (Temporal Cx; n = 3) and 
motor neurons (MNs; n = 7) are shown.  Eigengene of Module Magenta clearly distinguish 
the MNs from the other nervous tissues.  Because negative module eigengene is prominent 
in the MNs, TFs whose expression negatively contributes to the eigengene of the Module 
Magenta may be specifically expressed in the MNs.  The number of TFs classified in each 
module is indicated in brackets. 
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Results Figure 8D  Expression levels of TFs significantly contributing to the eigengenes of 
the Module Magenta. 
The WGCNA reveals that six TFs have significant positive contribution to the eigengene of 
the Module Magenta, whereas four TFs have significant negative contribution to it, as indi-
cated in parentheses.  As expected, negatively contributing four TFs are specifically ex-
pressed in the motor neurons (MN).  The color key at the top directs expression levels of TFs.  
Cx, cortex; Hippo, hippocampus. 
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Results Figure 8E  Correlation between every module eigengene and expression of 
ADARB1 and other marker genes. 
Eigengenes of some modules are significantly and uniquely correlated with expression of the 
selected genes, as indicated with the asterisk in cells of the heatmap.  Cell-types of the 
marker genes are indicated at the upside of the heatmap.  Labels for names of the marker 
genes for every cell-types are omitted but in alphabetical order [also see Materials and 
methods Table 6].  Modules are hierarchically clustered.  Pearson's rho is indicated with 
the color key at the top.  Neuron, ubiquitous neuronal marker genes; Glut, Inter, Purkinje, 
Astro, Oligo, Micro, Meningeal are marker genes for glutamatergic neuron, interneuron, 
Purkinje cell, astrocyte, oligodendrocyte, microglia and meningeal cell. 
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Results Figure 9  Flow chart for selecting candidate TFs for in vitro luciferase assay. 
ADARB1-regulatory TFs were predicted in silico while the present CAGE analysis on the 
human motor neurons (MNs) was progressed.  The candidate TFs were randomly selected 
from “SingleCor” to “ChIP & Motif” approaches, whereas two and one TFs were intendedly 
selected in “Pat. tissues” and “Put. links” ones.  In the "Pat. tissues" approach, two out of 
619 motoneuronal TFs were additionally selected, because they were highly expressed in the 
present CAGE data on the laser-captured MNs and decreased in multiple tissue types of pa-
tients with sporadic ALS.  In the "Put. links" approach, I selected only one TF whose molec-
ular link with FUS-ALS pathology had been implied in previous reports201,220.  The results of 
the present CAGE analysis on the laser-captured MNs revealed that some of the selected TFs 
in “SingleCor” and “Database” approaches were not expressed in the MNs, as indicated in the 
parentheses in their rows.  The number of the Results section of each predicting approach is 
shown in brackets.  By this selecting procedure, 32 motoneuronal and six non-motoneuronal 
TFs were selected; in addition to these, two motoneuronal and eight non-motoneuronal TFs 
had been already selected and prepared before the present study.  SingleCor, correlation be-
tween a single TF and ADARB1 expression; Database, the database ORTI for target genes of 
TFs; WGCNA, correlation between a TF in the module and ADARB1 expression; ChIP & 
Motif, presence of ChIP-seq signals and consensus motifs of TFs within the promoters; Pat. 
tissues, significantly decreased TFs in tissues of patients with sporadic ALS; Put. links, puta-
tive molecular links between ADARB1 regulation and FUS-linked ALS pathogenesis. 
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5.  DISCUSSION 
5-1.  MN-specific regulation of ADARB1 expression 
The CAGE analysis on the laser-captured MNs revealed both the active promoters of 
ADARB1 and the profile of gene expression in the human MNs.  Based on this CAGE data 
and the previous multiple data, the present in vitro luciferase assay demonstrated that many 
TFs could regulate ADARB1 expression in the MNs. 
5-1-1.  CAGE may detect higher transcriptional activity specific to the human MNs 
Although relatively fewer CAGE signals were obtained in the MNs, these signals were highly 
correlated between the two biological replicates of the MNs and independent from the signals 
in the control technical replicates of the dorsal horns and white matter [see Results Figure 
1B].  Because RNAs are not seriously damaged through the procedure of the laser-capture 
microdissection221, this independent correlation may reflect the difference in transcriptional 
activity but not the procedure for sampling between the MNs and the controls.  Therefore, 
this result indicates that these CAGE signals confidently represent higher transcriptional ac-
tivity in the MNs.  In other words, this study provides valuable genome-wide high transcrip-
tional activity at a nucleotide level specific to the human MNs for the first time.  Importantly, 
CAGE signals around ADARB1 in the MNs differed from those in the dorsal horns and white 
matter, suggesting that MN-specific enhancers regulate ADARB1 expression in a MN-specific 
 108 
way.  Based on this CAGE data of the MNs and the public data10,22,30,178, I defined the p2 and 
the p1 promoters as active promoters of ADARB1 in the MNs [see Results Figure 2B]. 
5-1-2.  ADARB1 expression may be differently regulated from the mouse ADAR2 gene 
Consistent with a previous report of species-specificity in the DNA sequences of promoters80, 
the present study confirms poor conservation between humans and mice in the position and 
DNA sequences of their ADAR2 gene alternative promoters [see Results Figures 2B-D and 
3].  In a similar way, consistent with previous reports describing species-specificity between 
humans and mice in the repertories of their TFs47 and their transcriptomes83,84, I found poor 
conservation in expression and repertoire of the motoneuronal TFs between the two species 
[see Results Figure 7A].  Since signals detected by CAGE and RNA-seq in the same tissue 
type are highly correlated222, the modest correlation in expression of the human and mouse 
motoneuronal TFs demonstrated in the present study may reflect differences between these 
two species rather than methodological differences between CAGE and RNA-seq [see Re-
sults Figure 7B].  Hence, the present study indicates that expression of human ADARB1 is 
regulated at different alternative promoters by different motoneuronal TFs from the mouse 
counterparts and that mice might be improper for an in vivo experimental model to examine a 
role of human ADARB1-regulatory TFs in the human MNs. 
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5-1-3.  ADARB1 expression in the MNs may be regulated by an MN-specific set of mul-
tiple TFs in its alternative promoter level 
So far, regulatory function of only one non-motoneuronal TF TP53 has been validated by in 
vitro luciferase assay using yeast and an osteosarcoma cell line for an ADARB1 promoter that 
had been differently defined from the present study (i.e., in the region about 1.1 kb upstream 
of the present p2 promoter)148.  Aside from that TP53, the present luciferase assay newly de-
termined 33 motoneuronal and 13 non-motoneuronal TFs as ADARB1-regulatory TFs [see 
Results Figure 10].  The presence of possible multiple ADARB1-regulatory TFs is con-
sistent with previous reports that TFs regulate gene expression in cooperative and redundant 
manners39,48,54,59–63 via their tissue-specific regulatory network59,64–66 and expression47 while 
mutually buffering their effects on promoters56. 
 Among the ADARB1-regulatory TFs determined in the present study, which ones are 
specifically expressed in the MNs?  According to a previous report defining the tis-
sue-specificity of TFs and their ability to be a tissue-specific hub48 and an additional analysis 
in the present study on expression patterns of TFs in human tissues and cells with the publicly 
available RNA-seq data (the Data Set 1 and 2), expression of the 10 examined motoneuronal 
TFs was MN-specific (AR, ESRRG, HOXB7, ID4, KLF7, MLLT11, RXRG, ZEB1, ZEB2 
and ZFPM2) [summarized in Results Table 8A; Discussion Figures 1A and 1B].  Alt-
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hough a tissue specific score of ESRRG (0.97) was slightly below the previously defined 
threshold (i.e., 1.0), the RNA-seq data clearly guaranteed its tissue-specificity; tis-
sue-specificity of MLLT11, ZEB1 and ZEB2 whose score was unavailable has been already 
reported223,224.  Consistent with the results of the present WGCNA determining AR as 
MN-specific [see Results Figure 8D], AR was previously defined as a tissue-specific hub; in 
addition to AR, RXRG also previously defined as a tissue-specific hub. 
 Protein-protein interactions204 among the examined motoneuronal TFs and other 
basic transcriptional machinery (e.g., subunits of RNA polymerase II) revealed that there was 
one large activating TF complex: this putative TF complex was composed of eight activators 
(ARNT, CREB1, ENO1, ESRRG, HIF1A, MAX, NR3C1 and NR3C2) and interacted with 
the basic transcriptional machinery via ARNT, ENO1, MAX and NR3C1 [Discussion Figure 
2].  Consistent with a previous report that protein-protein interaction of TFs consists of both 
TFs ubiquitously expressed in many tissue-types and ones specifically expressed in a fewer 
tissue-types48, this putative complex may exist in an MN-specific way because of MN-specific 
expression of ESRRG.  Moreover, because the present CAGE data on the laser-captured 
MNs showed high expression of most of these TFs [see Results Table 8A], all of these TFs 
belonged to the TF modules in the largest module cluster that might regulate ADARB1 ex-
pression in neurons in the present WGCNA (i.e., Module Black, Pink, Red, Tan and Tur-
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quoise) [see Results Figure 8B], and because ChIP-seq signals and/or consensus motifs of six 
TFs (ARNT, CREB1, ENO1, HIF1A, MAX and NR3C1) existed within the p2 and the p1 
promoters that were active in the MNs [see Results Figure 10A], this putative TF complex 
could regulate ADARB1 expression in an MN-specific manner.  This expectation is indirect-
ly supported by a previous report showing positive correlation between MAX expression and 
the whole RNA editing levels in human tissues225.  Activity of ARNT and CREB1 in the p1 
promoter could be indirect through selectively activating transcription at the p13@ whose ac-
tivity was significantly correlated with that at the p1@ [see Results Figure 4B].  Although 
both AR and MXI1 also interacted with the putative TF complex [see Discussion Figure 2], 
neither of these two TFs activated the p2 nor the p1 promoters in the present luciferase assay; 
this discrepancy between the expectation and the results of the present luciferase assay could 
be caused from the present experimental design that each of these TFs was singly transfected 
into HeLa cells together with the promoter construct or the lack of intracellular condition that 
requires activation of these TFs.  AR might require external addition of its ligand to bind its 
target, and MXI1 exclusively binds to its targets by forming a heterodimer with MAX226.  On 
the other hand, the other universal activators, ID4, KLF7, NFIA and ZEB1, were independent 
from the putative TF complex.  Therefore, these universal activators possibly contribute to 
other TF complexes regulating ADARB1 expression in the MNs. 
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 The present luciferase assay demonstrates that the 10 motoneuronal TFs did not ac-
tivate the p1 promoter but activated the p3/p4 promoter, whose transcriptional activity in the 
MNs was below the detection limit in the present CAGE analysis [see Results Figure 10A].  
Hence, as implied in the present in silico analyses [see Results Figures 4B and 4C and Re-
sults Table 5], the endogenous p3/p4 promoter in the MNs could be independently regulated 
as actively as the p2 and the p1 promoters, based on the selective activation of the p3/p4 pro-
moter by these 10 TFs and possibly on epigenetic modifications around it.  Indeed, moto-
neuronal TFs HOXB7 and MEF2A and a non-motoneuronal TF FOXB1 suppressed the p1 
promoter but oppositely activated the p3/p4 promoter, implying their putative role in shifting 
transcription from the p1 promoter to the p3/p4 promoter, as demonstrated in the expanded 
memory T cells203 [see Results Figure 4C]. 
 In the present luciferase assay demonstrated that most non-motoneuronal TFs were 
competent to regulate transcription at one or more of the four ADARB1 promoters.  Because 
these non-motoneuronal TFs are expressed in adult tissues other than the MNs or fetal tissues, 
they may play their regulatory role of ADARB1 expression in those tissues. 
 In short, in the human MNs, each of the four ADARB1 promoters may be redundantly 
regulated to some extent by a different MN-specific set of multiple TFs; these TFs may keep 
the p2 and the p1 promoters active but the others rather quiescent, thereby complicatedly reg-
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ulating the total expression levels of ADARB1 in the MNs in its alternative promoter level. 
5-2.  Implication for the ALS pathogenesis 
Providing knowledge of the putative regulatory mechanism of ADARB1 expression in the 
human MNs, the present study enables to infer roles of the ADARB1-regulatory motoneuronal 
TFs in the pathogenesis of sporadic ALS.  The aforementioned putative complicated regula-
tion of ADARB1 expression indicates that complicated causative abnormalities may underlie 
the down-regulation of ADARB1 in the patients' MNs: abnormalities of not a single but multi-
ple TFs may underlie the down-regulation of ADARB1 in the patients' MNs, and such abnor-
malities possibly have some variation among the individual patients.  Indeed, the present 
analysis of the public data showed that the activators of the ADARB1 promoters MLLT11 and 
ZEB1 apparently decreased in the MNs of some but not all of the 13 patients with sporadic 
ALS166 [see Discussion Figure 1A]. 
 What kinds of abnormalities related to the ADARB1-regulatory TFs could cause the 
down-regulation of ADARB1 in the patients' MNs?  In accordance with the working hypoth-
esis in the present study, one possible abnormality is the age-dependent decrease of the 
ADARB1-regulatory TFs, whose expression is inherently low in the patients' MNs because of 
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alternative alleles at eQTL of these TFs; inherently low expression of the other TFs whose 
expression is rather constant throughout the life might also underlie the down-regulation of 
ADARB1 [Discussion Figure 3].  Indeed, according to a previous report that comprehen-
sively defines all genes whose expression changes with aging in human tissues86, 70 moto-
neuronal TFs are significantly decreased with aging, including MLLT11 that was demon-
strated in the present study as the activator of the p1, the p13 and the p3/p4 promoters [see 
Results Table 8A].  In addition, results of exome-sequencing (ALS Variant Server206 and 
ALS Data Browser207) and genome-wide association studies (ALS Gene208) on the patients 
with sporadic ALS report many SNPs at eQTL158 of the 10 examined motoneuronal TFs, in-
cluding MLLT11 [Discussion Table 1].  Although an exact effect of SNPs at eQTL in the 
MNs is uncertain, the patients in the investigated cohort have more homozygous minor alter-
native alleles at eQTL that are associated with low expression of MLLT11 than the homozy-
gous major reference alleles of this motoneuronal TF.  In other words, these homozygous 
minor alternative alleles at eQTL of MLLT11 could cause this TF to be inherently less ex-
pressed in the patients' MNs, resulting in low basal expression of ADARB1.  Because 
MLLT11 is a neuron-specific marker223 highly expressed in the MNs in the present CAGE 
and the previous RNA-seq data [see Discussion Figure 1A and Results Table 8A], MLLT11 
may have its MN-specific regulatory role in gene expression.   Based on this series of indi-
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rect evidence, decrease of MLLT11 in the laser-captured MNs166,168, the whole spinal cords193, 
and motor cortices194,195 of the patients with sporadic ALS implies that such decrease might be 
not responsive but could contribute to the down-regulation of ADARB1 in the patients' MNs. 
 In addition to the age-dependent decrease of the ADARB1-regulatory TFs, the 
down-regulation of ADARB1 could also be caused by change in their quality which, for in-
stance, might be due to aberrant alternative splicing or post-translational modifications and by 
SNPs at eQTL of ADARB1 within its promoters and enhancers [Discussion Figure 4].  Alt-
hough the latter two are rather age-independent factors, these three abnormalities related to 
the ADARB1-regulatory TFs may have mutually not exclusive but summative effects on the 
down-regulation of ADARB1.  Although several studies have already attempted but failed to 
explain its pathogenesis with the repeat number of CAG in AR gene227–229 (i.e., the quality of 
AR protein), all of these three possible abnormalities related to the ADARB1-regulatory TFs 
should be considered when the cause of the down-regulation of ADARB1 in the patients' MNs 
is further examined in the future. 
 Are abnormalities of the motoneuronal TFs regulating the p2 and the p1 promoters in 
the MNs enough to cause the down-regulation of ADARB1 in the patients' MNs?  The an-
swer to this question might be "No," because the public high-throughput data on the patients' 
MNs166,168,192 showed decrease of RXRG, the selective activator for the p3/p4 promoter [see 
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Results Figure 10A and Results Table 8A].  RXRG is a tissue-specific hub TF48 and pref-
erentially binds to its target DNA sequences with mCpG53 that are enriched within actively 
transcribed gene bodies77–79, suggesting its MN-specific role in regulating the endogenous 
mCpG-rich p3/p4 promoter within the gene body of ADARB1 in the MNs.  Hence, the de-
crease of RXRG observed in the patients' MNs might have contributed to its pathogenesis.  
If ADAR2 proteins expressed from the p3/p4 promoter are competent for RNA editing at Q/R 
site of GluA2, the p3/p4 promoter could be compensatively activated via its dynamic and in-
dependent regulation upon impairment of activity of the p2 and p1 promoters in the MNs.  
Therefore, to further infer contribution of such p3/p4 promoter-selective activators to the 
pathogenesis of sporadic ALS, enzymatic competence of the ADAR2 proteins expressed from 
the p3/p4 promoter (and might also from the p13 promoters) should be determined first. 
 In short, when the p2 and the p1 promoters of ADARB1 are regulated by multiple TFs 
in the MNs, abnormalities of multiple TFs may cause the down-regulation of ADARB1 in the 
MNs of patients with sporadic ALS. 
5-3.  Assessment of the approaches for predicting and validating ADARB1-regiulatory 
TFs in the present study 
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Here, I briefly assess all the approaches adopted in the present study to predict 
ADARB1-regulatory TFs as comprehensive as possible, based on (1) data availability, (2) ef-
ficiency of that prediction in narrowing down the candidates from all the 1,334 motoneuronal 
TFs, (3) consistency of that prediction with the results of the present luciferase assay of the 34 
motoneuronal TFs, and (4) possible bias in that approach [Discussion Table 2].  Also, here I 
denote limitations of the present luciferase assay for validating ADARB1-regulatory TFs. 
5-3-1.  Prediction from correlation in expression between TFs and ADARB1 
Using (1) abundantly available high-throughput public data of gene expression profiles, (2) 
calculating correlation can efficiently list up the candidate TFs by setting an arbitrary 
threshold of the correlation coefficient (as in the Results Section 4-4-1) or statistical signifi-
cance (as in the Results Section 4-4-3).  Surprisingly, for both of these predicting approaches, 
(3) the present luciferase assay showed that the candidates tended to activate the p2, the p13 
and the p3/p4 promoters compared to the p1 promoter; this tendency remained even at a lower 
threshold of Spearman' rho (|rho| > 0.4 in the Results Section 4-4-1) [the parentheses in Dis-
cussion Table 2], suggesting preference of these approaches to predict TFs selectively acti-
vating the promoters other than the p1 promoter.  Although these correlation-based ap-
proaches achieved the most profitable prediction in the present study, (4) these approaches are 
clearly under bias because these were based only on the total expression of ADARB1 and dis-
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missed individual activity of the ADARB1 alternative promoters that was tested by the present 
luciferase assay.  In other words, calculating correlation in every CTSS activity between TFs 
and ADARB1 in the human tissues might enable to predict ADARB1-regulatory TFs more ac-
curately in the alternative promoter level. 
5-3-2.  Prediction from the database for putative target genes of TFs 
Based on experimental validation (e.g., ChIP assay and luciferase assay), (1) the public data-
base ORTI180 suggested only two motoneuronal TFs as a putative ADARB1-regulatory TF, 
enabling to (2) regard these two out of the 1,334 TFs as the candidates.  The present lucifer-
ase assay showed that (3) a candidate motoneuronal TF AR and another candidate 
non-motoneuronal TF FOXP3 did not activate and strongly activated all the ADARB1 pro-
moters, respectively [see Results Figures 10A and 10B].  (4) Possible bias in this approach 
is a different definition of the promoter regions of ADARB1 between the present study and 
previous reports curated by this database. 
5-3-3.  Prediction from public data of ChIP-seq and consensus motifs of TFs 
(1) The database ChIP-Atlas188 and the previous reports52,53,55,189,190 provided the ChIP-seq and 
consensus motif data of approximately 25% of the 1,334 motoneuronal TFs, respectively [see 
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Results Table 5], (2) only 18% and 45% of which were regarded as the candidates based on 
presence of their signals and motifs within the promoters, respectively.  However, the pre-
sent in vitro luciferase assay revealed that (3) only about a half of the examined TFs whose 
data were available really activated the promoter within which their ChIP-seq signals or con-
sensus motifs existed or was inactive for the promoter within which the signals or motifs were 
absent.  (4) The possible bias in the prediction using the ChIP-seq data is the 
cell-type-specific intracellular environment (e.g., difference in activity of the ADARB1 alter-
native promoters and other co-expressed TFs with which the examined TF binds to the pro-
moters in that cell); and non-functional or weak binding of the examined TF that is solely in-
sufficient to activate or suppress the promoter56,63.  On the other hand, (4) the possible bias in 
the prediction using the consensus motifs is variability of these motifs: although the consen-
sus motifs can vary depending on binding manners of TFs and contexts of DNA 
sequences53,55,61,230, not all those variants are yet to be determined. 
5-3-4.  Extraction of TFs decreasing in the tissues of patients with sporadic ALS 
(1) High-throughput data of differentially expressed gene analyses on the tissues of patients 
with sporadic ALS have been accumulating in public, and such data are expected to increase 
further in the future.  However, (2) this approach did not straightforwardly allow the putative 
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causative TFs to surface from all the motoneuronal TFs, because approximately a half of the 
1,334 motoneuronal TFs decreased in one or more data sets of the studies on the patients' tis-
sues166,168,192–195 [see Results Figure 9].  The present luciferase assay showed that (3) nearly a 
half of the candidate TFs in this approach activated at least one of the ADARB1 promoters; 
this also holds true when I consider only the TFs decreasing in the patients' MNs166,168 and/or 
the whole spinal cords193 [the parentheses in Discussion Table 2].  (4) The data of the dif-
ferentially expressed gene analyses may not only be under bias in the original statistical 
method and their procedure for sample collection but also in indistinguishable co-existence of 
the causative and responsive change195 and dismissing differential expression among the indi-
vidual patients.  The bias in sample collection is critical especially for the data using the la-
ser-captured MNs, because the patients' single MN harboring the sufficiently edited GluA2 at 
its Q/R site contains much more ADAR2 mRNA than the one harboring the unedited 
GluA2120; therefore, when the total RNA is extracted from the pooled samples of the la-
ser-captured MNs, the crucial down-regulation of ADARB1 in the degenerated MNs could be 
masked by relatively preserved ADAR2 mRNAs in less degenerated MNs that could have 
been collected more often.  Indeed, in the public data of the MNs used in this study, 
ADARB1 in the patients' MNs was insignificantly down-regulated or expressed in near levels 
to that in the control subjects, depending on the individuals.  In addition, given the afore-
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mentioned possibility that abnormalities of the ADARB1-regulatory TFs might vary to some 
extent among the individual patients, a statistical analysis on the transcriptomes of a cohort of 
the patients could fail to detect such individual difference.  Hence, such bias altogether sug-
gests that statistically insignificant change in expression of the motoneuronal TFs in the pa-
tients' MNs may never exclude those TFs from the list of the putative causative TFs 
down-regulating ADARB1 expression in the MNs, leaving interpreting data of the differen-
tially expressed gene analyses quite difficult without examining their regulatory role on the 
ADARB1 promoters by luciferase assay. 
5-3-5.  Extraction of TFs in possible molecular cascades of pathogenesis of mutant 
FUS-linked ALS 
(1) This approach utilized many previous data available in public but (2) listed so many can-
didates [see Results Figure 9].  Although (3) about half of the motoneuronal TFs listed in 
this approach really activated one or more of the tested ADARB1 promoters, (4) this approach 
is based on the poorest rationale, because molecular links between the pathogenesis of spo-
radic and mutant FUS-linked ALS yet to be revealed.  The present results in this approach 
might be rather useful to survey the pathogenesis of mutant FUS-linked ALS in the future 
when most ADARB1-regulatory TFs causing sporadic ALS are determined. 
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5-3-6.  Limitations of the present luciferase assay for validating ADARB1-regulatory 
TFs 
The ChIP-seq and consensus motifs whose data were used in the present in silico prediction 
are mainly for the TFs highly expressed in culture cell lines, and difference in expression lev-
els of TFs between the MNs and the culture cell lines may underlie the poor availability (ap-
proximately 25%) for these data of the motoneuronal TFs [see Results Table 5].  Moreover, 
as already mentioned, the prediction based on these data is not highly accurate, implying the 
possible false negative in this prediction.  Nevertheless, the TFs extracted by the present in 
silico predicting approaches did demonstrate their regulatory function for the ADARB1 pro-
moters in the present luciferase assay, suggesting their faithful regulatory roles in ADARB1 
expression. 
 It is unclear to what extent the demonstrated regulatory function of the examined 
motoneuronal TFs for the ADARB1 promoters in the present luciferase assay using HeLa cells 
exactly recapitulates their function in the MNs, because the examined TFs demonstrated their 
function for the ADARB1 promoters in cooperation with other TFs that were co-expressed not 
in the MNs but in the HeLa cells, and because the tested promoters were independent from 
the original chromosomal environment and regulation by their enhancers.  Nevertheless, the 
examined motoneuronal TFs activating the ADARB1 promoters in the present luciferase assay 
 123 
using the HeLa cells may activate the endogenous ADARB1 promoters in the MNs as well.  
Although altering expression of the motoneuronal TFs in a cell line whose transcriptome 
mimics the MNs can reveal their true role in regulating ADARB1 expression in the MNs, such 
a cell line is currently unavailable.  Indeed, even iMNs have different transcriptome from the 
real MNs [see Discussion Figures 1A and 1B], possibly because of their immaturity231. 
5-4.  What should be done next, to explain why and how the down-regulation of 
ADARB1 in the MNs of patients with sporadic ALS occurs? 
The present study implies that abnormalities of the multiple ADARB1-regulatory TFs may 
underlie the down-regulation of ADARB1 in the MNs of patients with sporadic ALS, thereby 
establishing the entrance of the final goal to explain why and how such down-regulation of 
ADARB1 occurs in the patients' MNs.  Because of the aforementioned false negative results 
in the current in silico predicting approaches, other motoneuronal TFs that were not examined 
in the present in vitro luciferase assay can also regulate ADARB1 expression in the MNs.  
Therefore, to achieve this final goal, it still requires to determine additional 
ADARB1-regulatory TFs in the MNs and then to predict a crucial subset of the 
ADARB1-regulatory TFs for maintaining ADARB1 expression.  Besides, the present study 
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concentrated solely on the ADARB1 promoters to investigate the regulatory mechanism of 
ADARB1 expression; because transcriptional activity of the ADARB1 promoters in the MNs 
may be regulated by MN-specific enhancers [see Results Figure 2A], regulatory effects of 
such enhancers on ADARB1 expression in the MNs should be investigated in the future. 
 To determine additional ADARB1-regulatory TFs in the MNs, it is predictable to use 
information of protein-protein interactions of the unexamined TFs with the activators deter-
mined in this study and positions of ChIP-seq signals and consensus motifs of the unexamined 
TFs within the ADARB1 promoters, although physical interaction among TFs is not neces-
sarily required for their cooperative function61.  Regulatory function of newly predicted 
ADARB1-regulatory TFs on the ADARB1 promoters should be examined by in vitro luciferase 
assay in the same way as the present study. 
 What and how many TFs may contribute to the down-regulation of ADARB1 in the 
patients' MNs?  Answering this difficult question demands prediction of a crucial subset of 
the ADARB1-regulatory TFs to maintain ADARB1 expression.  In this regard, because genes 
specifically expressed in a sub-region of the brain have been shown to significantly associate 
with diseases in the brain regardless of their expression levels85, the ADARB1-regulatory TFs 
expressed not ubiquitously but specifically in the MNs should be concerned in no matter what 
levels they are expressed in these neurons.  As described above, to ask if roles of the p3/p4 
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and p13 promoter-selective motoneuronal TFs can be crucial, unexamined enzymatic activity 
of ADAR2 expressed from transcripts with Exon 0 or Exon 1a should be determined.  In ad-
dition, one executable way is to deduce the crucial subset of the TFs by seeking SNPs at 
eQTL158,232 of the TFs around the CAGE signals in the MNs from the patients' genome se-
quences available on dbGaP website (https://www.ncbi.nlm.nih.gov/gap), where authorized 
users are allowed to access such data.  This approach only requires additional in silico anal-
yses and the authorized accession to dbGaP; notably, the GTEx Consortium updated data of 
eQTL during preparing this dissertation, and data of eQTL in human spinal cord tissues are 
now available on its website (latest version V7; https://www.gtexportal.org/home/).  Other 
ways are to in vitro knockdown or to simulate in silico the knockdown of the multiple 
ADARB1-regulatory TFs, thereby assessing resultant change in the ADARB1 expression; 
however, either way requires a currently unavailable cell line faithfully mimicking the real 
adult human MNs for gaining valid results and validating the simulated results, respectively.  
Adopting the approaches suggested here and additional ones that may be available in the fu-
ture will lead to depict the whole picture of the pathogenesis of sporadic ALS. 
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Discussion Figure 2  Protein-protein interactions among the examined TFs and other pro-
teins in the transcriptional machinery. 
Interactome retrieved from STRING v10.5 based on the experiments, databases and 
co-expression with > 0.15 confidence is shown.  Nodes of the examined TFs are colored, 
based on their activating or suppressing effect on the four ADARB1 promoters, respectively 
(see the example chart at the top right).  The legend at the top left directs the nodes of the 
transcriptional machinery.  The size of nodes and the thickness of edges are in accord with 
the expression level of those proteins and the confidence of the interactions, respectively.  
Some interactions mentioned in the text are highlighted with red edges.  TFs separated by 
line at the bottom right show no reported interaction with the others.  
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Discussion Figure 3  Implication for the pathogenesis of sporadic ALS based on the work-
ing hypothesis in this study with some modifications. 
ADARB1 expression is cooperatively regulated by multiple TFs classified as TF-1 (top left) 
and TF-2 (top right) groups.  The TF-1 decreases with aging even in the motor neurons 
(MNs) of the healthy (e.g., MLLT11), while the TF-2 is constantly expressed throughout the 
life (e.g., ENO1).  In the MNs of patients with sporadic ALS (red), such ADARB1-regulatory 
TFs are inherently fewer compared to the healthy (black) due to alternative alleles at expres-
sion quantitative trait loci of these TFs decreasing their basal expression.  Thereby, the TF-1 
in the patients' MNs may decrease below the threshold for maintaining the required expres-
sion of ADARB1 (blue horizontal line) much earlier than the healthy (tTF-1).  When expres-
sion levels of key ADARB1-regulatory TFs are all below the threshold (tTF(sum)), ADARB1 may 
begin to be down-regulated in the patients' MNs.  Exp, expression level; TF, transcription 
factor. 
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Discussion Figure 4  Possible causes down-regulating ADARB1 expression in the MNs of 
patients with sporadic ALS. 
There are three possible causes down-regulating ADARB1 expression in the patients' MNs: 1, 
decrease of the ADARB1-regulatory TFs; 2, qualitative abnormality of the TFs; 3, SNPs 
within the cis-regulatory regions of ADARB1 (i.e., enhancers and the four alternative promot-
ers) that weaken binding affinity of the TFs to these regions.  As indicated in the question 
mark, however, it is unclear whether or not transcription at the p3/p4 and/or the p13 promot-
ers is activated for compensation, when transcriptional activity at the dominant p1 and sup-
portive p2 promoters decreases.  SNPs, single nucleotide polymorphisms; TF, transcription 
factor. 
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6.  CONCLUSION 
Based on the CAGE analysis on the laser-captured human MNs, the present study defined two 
out of the four promoters as active ADARB1 promoters in the MNs, predicted the 
ADARB1-regulatory TFs in the MNs by in silico analyses on the multiple public data, and 
then surveyed their regulatory roles for each of the ADARB1 promoters by in vitro luciferase 
assay for the first time [Conclusion Figure].  The present study lists the putative 
ADARB1-regulatory motoneuronal TFs and enables to further investigate the regulatory 
mechanism of ADARB1 expression in the MNs.  This knowledge is vital to uncover the ab-
normal molecular cascade underlying the pathogenic down-regulation of ADARB1 in the MNs 
of patients with sporadic ALS.  Hence, even though further studies should be conducted, I 
believe that the present study propels one step forward for understanding the whole image of 
the pathogenesis of this fatal disease. 
  
 135 
Conclusion Figure  The inferred regulatory mechanism of ADARB1 expression in the hu-
man motor neurons (MNs). 
Based on the present CAGE analysis on the human MNs and a number of the previous data, 
the present study defined the four ADARB1 promoters and 1,334 TFs expressed in the MNs 
(the motoneuronal TFs).  The present in vitro luciferase assay of the selected 34 motoneu-
ronal TFs on the ADARB1 promoters showed that the p2 and p1 promoters active in the MNs 
could be regulated by a different set of multiple motoneuronal TFs, respectively (two dotted 
ellipses within the red rectangle).  Circles colored in red, blue, green and black denote the 
universal activators for all the four promoters, the universal suppressor for all the four pro-
moters, the selective activators/suppressors and the inactive TF, respectively.  Stars colored 
in red and green denote the TFs whose expression was decreased in tissues of patients with 
sporadic ALS.  The 1,300 motoneuronal TFs remains unexamined by luciferase assay, and 
any regulatory effects from enhancers onto the promoter activity are beyond the scope of this 
study (outside the red rectangle). 
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